<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">84108</article-id><article-id pub-id-type="doi">10.7554/eLife.84108</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>A human-specific motif facilitates CARD8 inflammasome activation after HIV-1 infection</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-295339"><name><surname>Kulsuptrakul</surname><given-names>Jessie</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3881-4686</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-188407"><name><surname>Turcotte</surname><given-names>Elizabeth A</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-103543"><name><surname>Emerman</surname><given-names>Michael</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4181-6335</contrib-id><email>memerman@fredhutch.org</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-188405"><name><surname>Mitchell</surname><given-names>Patrick S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8375-9060</contrib-id><email>psmitche@uw.edu</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00cvxb145</institution-id><institution>Molecular and Cellular Biology Graduate Program, University of Washington</institution></institution-wrap><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Division of Immunology and Pathogenesis, University of California, Berkeley</institution><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Divisions of Human Biology and Basic Sciences, Fred Hutchinson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00cvxb145</institution-id><institution>Department of Microbiology, University of Washington</institution></institution-wrap><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kirchhoff</surname><given-names>Frank</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032000t02</institution-id><institution>Ulm University Medical Center</institution></institution-wrap><country>Germany</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Davenport</surname><given-names>Miles P</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03r8z3t63</institution-id><institution>University of New South Wales</institution></institution-wrap><country>Australia</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>07</day><month>07</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e84108</elocation-id><history><date date-type="received" iso-8601-date="2022-10-12"><day>12</day><month>10</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-07-06"><day>06</day><month>07</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-10-04"><day>04</day><month>10</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.10.04.510817"/></event></pub-history><permissions><copyright-statement>Â© 2023, Kulsuptrakul et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Kulsuptrakul et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-84108-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-84108-figures-v2.pdf"/><abstract><p>Inflammasomes are cytosolic innate immune complexes that assemble upon detection of diverse pathogen-associated cues and play a critical role in host defense and inflammatory pathogenesis. Here, we find that the human inflammasome-forming sensor CARD8 senses HIV-1 infection via site-specific cleavage of the CARD8 N-terminus by the HIV protease (HIV-1<sup>PR</sup>). HIV-1<sup>PR</sup> cleavage of CARD8 induces pyroptotic cell death and the release of pro-inflammatory cytokines from infected cells, processes regulated by Toll-like receptor stimulation prior to viral infection. In acutely infected cells, CARD8 senses the activity of both de novo translated HIV-1<sup>PR</sup> and packaged HIV-1<sup>PR</sup> that is released from the incoming virion. Moreover, our evolutionary analyses reveal that the HIV-1<sup>PR</sup> cleavage site in human CARD8 arose after the divergence of chimpanzees and humans. Although chimpanzee CARD8 does not recognize proteases from HIV or simian immunodeficiency viruses from chimpanzees (SIVcpz), SIVcpz does cleave human CARD8, suggesting that SIVcpz was poised to activate the human CARD8 inflammasome prior to its cross-species transmission into humans. Our findings suggest a unique role for CARD8 inflammasome activation in response to lentiviral infection of humans.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>HIV-1</kwd><kwd>inflammasome</kwd><kwd>CARD8</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>DP2 AI 154432-01</award-id><principal-award-recipient><name><surname>Mitchell</surname><given-names>Patrick S</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100012643</institution-id><institution>Edward Mallinckrodt Jr. Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Mitchell</surname><given-names>Patrick S</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000026</institution-id><institution>National Institute on Drug Abuse</institution></institution-wrap></funding-source><award-id>DP1 DA051110</award-id><principal-award-recipient><name><surname>Emerman</surname><given-names>Michael</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>T32 GM007270</award-id><principal-award-recipient><name><surname>Kulsuptrakul</surname><given-names>Jessie</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>HIV-1 infection activates the human CARD8 inflammasome via innate immune recognition of HIV-1 viral protease activity.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>One of the primary selective pressures that shape viral adaptation to a new host, as well as tolerance to persistent infections, is the innate immune system (<xref ref-type="bibr" rid="bib15">Daugherty and Malik, 2012</xref>; <xref ref-type="bibr" rid="bib45">Parrish et al., 2008</xref>). One class of innate immune sensors forms cytosolic immune complexes called inflammasomes, which initiate inflammatory signaling upon pathogen detection or cellular stress (<xref ref-type="bibr" rid="bib9">Broz and Dixit, 2016</xref>). Inflammasome activation is critical for host defense against a wide range of pathogens; however, auto-activating mutations in inflammasome-forming sensors can also initiate inflammatory pathogenesis that drives autoinflammatory and autoimmune disorders (<xref ref-type="bibr" rid="bib62">Steiner et al., 2018</xref>; <xref ref-type="bibr" rid="bib63">Taabazuing et al., 2020</xref>).</p><p>The inflammasome-forming sensor caspase recruitment domain-containing protein 8 (CARD8) consists of a disordered N-terminus, a function-to-find domain (FIIND), and a caspase activation and recruitment domain (CARD) (<xref ref-type="bibr" rid="bib63">Taabazuing et al., 2020</xref>). The FIIND, comprised of ZU5 and UPA subdomains, undergoes self-cleavage resulting in two non-covalently associated fragments (<xref ref-type="bibr" rid="bib17">DâOsualdo et al., 2011</xref>; <xref ref-type="bibr" rid="bib63">Taabazuing et al., 2020</xref>). Proteasome-dependent degradation of the N-terminus leads to the release and assembly of the C-terminal UPA-CARD, serving as a platform for the recruitment and activation of caspase-1 (CASP1). Activated CASP1 initiates a lytic, programmed cell death called pyroptosis and the release of pro-inflammatory cytokines including interleukin (IL)-1Î² and IL-18 (<xref ref-type="bibr" rid="bib9">Broz and Dixit, 2016</xref>; <xref ref-type="bibr" rid="bib20">Fink and Cookson, 2005</xref>). To prevent aberrant release of the UPA-CARD, the dipeptidyl peptidases 8 and 9 (DPP8/9) form an inhibitory complex with CARD8 (<xref ref-type="bibr" rid="bib58">Sharif et al., 2021</xref>).</p><p>The CARD8 inflammasome can be activated by several triggers. For example, disruptions to protein homeostasis, including direct (e.g. Val-boroPro) and indirect (e.g. CQ31) inhibition of DPP8/9, cause CARD8 inflammasome activation (<xref ref-type="bibr" rid="bib28">Johnson et al., 2020</xref>; <xref ref-type="bibr" rid="bib27">Johnson et al., 2018</xref>; <xref ref-type="bibr" rid="bib49">Rao et al., 2022</xref>). Several recent examples also highlight CARD8 inflammasome activation in response to pathogens (<xref ref-type="bibr" rid="bib42">Nadkarni et al., 2022</xref>; <xref ref-type="bibr" rid="bib68">Tsu et al., 2023</xref>), including via its recognition of the enzymatic activity of the HIV-1 protease (HIV-1<sup>PR</sup>) (<xref ref-type="bibr" rid="bib69">Wang et al., 2021</xref>). For example, treatment of HIV-1 latently infected cells with certain nonnucleoside reverse transcriptase inhibitors (NNRTIs), including efavirenz (<xref ref-type="bibr" rid="bib69">Wang et al., 2021</xref>) or doravirine-like analogs including the pyrimidines Pyr01 (<xref ref-type="bibr" rid="bib3">Balibar et al., 2023</xref>), enforce the cytosolic dimerization of the HIV-1<sup>PR</sup> and results in CARD8 inflammasome activation in primary CD4+ T cells and humanized mouse models (<xref ref-type="bibr" rid="bib14">Clark et al., 2022</xref>). HIV-1<sup>PR</sup> cleavage of the N-terminus of CARD8 causes proteasome-dependent degradation of the CARD8 N-terminal fragment (<xref ref-type="bibr" rid="bib69">Wang et al., 2021</xref>). This âfunctional degradationâ liberates the UPA-CARD fragment for inflammasome assembly and activation, analogous to viral protease sensing by the inflammasome-forming sensor NLRP1 (<xref ref-type="bibr" rid="bib51">Robinson et al., 2020</xref>; <xref ref-type="bibr" rid="bib54">Sandstrom et al., 2019</xref>; <xref ref-type="bibr" rid="bib66">Tsu et al., 2021a</xref>; <xref ref-type="bibr" rid="bib67">Tsu et al., 2021b</xref>; <xref ref-type="bibr" rid="bib47">PlanÃ¨s et al., 2022</xref>) in which the N-terminus of CARD8 functions as a molecular âtripwireâ to sense and respond to the enzymatic activity of HIV-1<sup>PR</sup> and other viral proteases (<xref ref-type="bibr" rid="bib11">Castro and Daugherty, 2023</xref>; <xref ref-type="bibr" rid="bib42">Nadkarni et al., 2022</xref>; <xref ref-type="bibr" rid="bib68">Tsu et al., 2023</xref>).</p><p>Here, we report that CARD8 can also sense acute HIV-1 infection via the detection of HIV-1<sup>PR</sup> activity. We find that priming of target cells via Toll-like receptor (TLR) agonists prior to HIV-1 challenge enhances CARD8-dependent cell death and is required for IL-1Î² secretion. Our evolution-guided studies reveal that CARD8 sensing of HIV-1 and other simian lentiviruses is dependent on a F59-F60 motif in human CARD8 that permits its sensing of HIV-1<sup>PR</sup>. This motif is absent in other primates that serve as reservoirs of simian immunodeficiency viruses (SIVs), and although both HIV-1<sup>PR</sup> and SIVcpz<sup>PR</sup> cleave and activate human CARD8, we find that neither are sensed by chimpanzee CARD8. Thus, our study reveals that the CARD8 inflammasome functions in the innate immune detection of HIV-1 replication. Moreover, our findings suggest that the evolution of the F59-F60 motif in humans gave rise to a human-specific host-virus interaction following the spillover of SIVcpz into humans, which may uniquely shape human innate immune responses to lentiviral infection.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>A human-specific motif allows CARD8 to detect protease activity from multiple HIV strains</title><p>The HIV-1 protease (HIV-1<sup>PR</sup>) cleaves human CARD8 between phenylalanine (F) 59 (P1) and F60 (P1â) (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="bibr" rid="bib69">Wang et al., 2021</xref>). While the amino acid P1 site, F59, is invariant among hominoids, gibbons, and Old World monkeys, only human CARD8 has a phenylalanine at the P1â site, F60 (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). The F59-F60 motif therefore must have arisen in the human lineage after the most recent common ancestor with chimpanzees and bonobos. The F59-F60 motif is also present in <italic>Homo neanderthalensis</italic> (i.e. Neanderthal) CARD8 (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), conservatively dating its emergence within the last million years (<xref ref-type="bibr" rid="bib21">Green et al., 2010</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>The F59-F60 motif allows human CARD8 to detect protease activity from multiple HIV strs.</title><p>(<bold>A</bold>) Phylogenetic alignment of primate CARD8 protein sequences. The HIV protease (HIV<sup>PR</sup>) cleavage site is indicated by a purple triangle between F59 (P1) and F60 (P1â). Numbering is based on human CARD8. (<bold>B</bold>) Depiction of the mCherry-CARD8 used in cleavage assays in (<bold>C and D</bold>). The predicted molecular weights (kDa) for full-length, FIIND-processed, or HIV<sup>PR</sup> cleavage products are indicated. FIIND, function-to-find domain; CARD, caspase activation and recruitment domain. (<bold>C</bold>) HEK293T cells were transfected with a construct encoding N-terminally mCherry-tagged wildtype (WT) CARD8 and indicated HIV proviral constructs, HIV-1<sub>LAI</sub>, HIV-1<sub>Q23</sub>, or HIV-2<sub>ROD</sub>, in the presence (â+â) or absence (âââ) of 10 ÂµM lopinavir, an HIV<sup>PR</sup> inhibitor. <italic>Top:</italic> Immunoblotting for anti-mCherry to detect the mCherry-CARD8 fusion protein. The full-length and FIIND-processed bands are indicated as well as the HIV<sup>PR</sup> cleavage product. The band at ~45 kDa is the result of cleavage by the 20S proteasome (<xref ref-type="bibr" rid="bib25">Hsiao et al., 2022</xref>). <italic>Middle</italic>: Immunoblotting with an anti-p24<sup>gag</sup> antibody showing Gag cleavage products p41<sup>gag</sup> and p24<sup>gag</sup>, and/or full-length Gag, p55<sup>gag</sup>. <italic>Bottom</italic>: Immunoblotting with anti-vinculin as a loading control. (<bold>D</bold>) HEK293T cells were transfected with a construct encoding N-terminally mCherry-tagged WT, F60L, or F60S CARD8 and indicated HIV proviral constructs. Immunoblotting and labeling of the blots as in (<bold>C</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84108-fig1-v2.tif"/></fig><p>In order to assess the significance of the human CARD8 F59-F60 motif, we established conditions required for HIV<sup>PR</sup> cleavage of CARD8 by co-expression of CARD8 and proviruses from two HIV-1 group M proviruses (HIV-1<sub>LAI</sub> subtype B and HIV-1<sub>Q23</sub> subtype A) as well as an HIV-2 isolate, HIV-2<sub>ROD</sub>. Indeed, we found that wildtype (WT) human CARD8 with an N-terminal mCherry fusion is cleaved upon transfection of HIV-1 and HIV-2 proviruses, resulting in an ~33 kDa product (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>, top blot). The band at ~45 kDa is the result of cleavage by the 20S proteasome and results in a non-functional product (<xref ref-type="bibr" rid="bib25">Hsiao et al., 2022</xref>). Cleavage of CARD8 in these experiments was dependent on the protease encoded by the <italic>Gag-Pol</italic> gene of these proviruses as the HIV<sup>PR</sup> inhibitor lopinavir (LPV) blocked both Gag processing of p55<sup>gag</sup> to p41<sup>gag</sup> and p24<sup>gag</sup> and CARD8 cleavage (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, top and middle blot). To evaluate the significance of the amino acid variation at the F60 P1â site of CARD8, we next replaced human CARD8 F60 (WT) with either a leucine (L; found in chimpanzee, bonobo, and gorilla) or a serine (S; found in gibbons and Old World monkeys) (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). HIV<sup>PR</sup> cleavage of WT human CARD8 (F60) was much more efficient than cleavage of human CARD8 F60L or F60S (<xref ref-type="fig" rid="fig1">Figure 1D</xref>), consistent with prior findings that an alanine at position 60 also blocks HIV<sup>PR</sup> (<xref ref-type="bibr" rid="bib69">Wang et al., 2021</xref>). These results indicate that species-specific variation at position 60 impacts CARD8 recognition of HIV<sup>PR</sup> activity.</p></sec><sec id="s2-2"><title>Natural variation in CARD8 alters sensing of SIVcpz protease activity</title><p>We next asked if HIV<sup>PR</sup> cleavage of CARD8 was an ancestral function of SIVcpz or if that functionality instead emerged following cross-species transmission and adaptation to humans. SIVcpz<sub>EK505</sub> and SIVcpz<sub>LB7</sub> represent lineages that gave rise to HIV-1 group N and M viruses, respectively (<xref ref-type="bibr" rid="bib5">Barbian et al., 2015</xref>; <xref ref-type="bibr" rid="bib30">Keele et al., 2006</xref>; <xref ref-type="bibr" rid="bib60">Sharp and Hahn, 2011</xref>). Like HIV-1 and HIV-2 proteases, we found that both SIVcpz proteases (SIVcpz<sup>PR</sup>) cleaved human CARD8 (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), suggesting that SIVcpz<sup>PR</sup> had a pre-existing ability to cleave human CARD8 prior to spillover. To deduce whether or not this cleavage is unique to humans, we also tested SIVcpz<sup>PR</sup> ability to cleave chimpanzee CARD8 (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) and F60L and F60S human CARD8 variants (<xref ref-type="fig" rid="fig2">Figure 2B</xref>) and found that none of the other CARD8 variants could be cleaved by SIVcpz<sup>PR</sup>. Moreover, SIVmac<sub>239</sub><sup>PR</sup> also cleaved WT human CARD8, an event that was greatly reduced when tested against the human CARD8 cleavage mutant F60A (<xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref>). These data suggest that SIVcpz<sup>PR</sup> was poised to cleave human CARD8 prior to its zoonosis to humans. Moreover, the F59-F60 motif that arose in the human lineage renders human CARD8 uniquely susceptible to cleavage at that position by a broad range of primate lentiviral proteases.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Natural variation in CARD8 alters sensing of SIVcpz<sup>PR</sup> activity.</title><p>(<bold>A</bold>) HEK293T cells were transfected with a construct encoding N-terminally mCherry-tagged human or chimpanzee (cpz) CARD8 and indicated provirus constructs. Immunoblotting was carried out for CARD8 cleavage, HIV/SIV protease (S/HIV<sup>PR</sup>) activity, and vinculin (loading control) as indicated. The S/HIV<sup>PR</sup> cleavage product is indicated by a purple triangle. FIIND, function-to-find domain. (<bold>B</bold>) HEK293T cells were transfected with a construct encoding N-terminally mCherry-tagged wildtype (WT), F60L, or F60S CARD8 and indicated proviral constructs. Immunoblotting was performed as in (<bold>A</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84108-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2âfigure supplement 1.</label><caption><title>SIVmac cleaves wildtype (WT) human CARD8.</title><p>HEK293T cells were transfected with a construct encoding N-terminally mCherry-tagged WT or F60A human CARD8 and indicated provirus constructs. Immunoblotting was carried out for CARD8 cleavage, HIV/SIV protease (S/HIV<sup>PR</sup>) activity, and vinculin (loading control) as indicated. The anti-p24<sup>gag</sup> antibody (for S/HIV<sup>PR</sup> activity) poorly cross-reacts with SIVmac<sub>239</sub>. The S/HIV<sup>PR</sup> cleavage product is indicated by a purple triangle. We note that SIVmac<sub>239</sub><sup>PR</sup> still partially cleaves CARD8 F60A. FIIND, function-to-find domain.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84108-fig2-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-3"><title>HIV-1 infection activates the inflammasome in primed THP-1 cells in a CARD8-dependent manner</title><p>We next sought to determine the significance of CARD8 cleavage and activation in the context of HIV-1 infection. Treatment with some NNRTIs induces premature Gag-Pol dimerization and HIV-1<sup>PR</sup> activity (<xref ref-type="bibr" rid="bib19">Figueiredo et al., 2006</xref>; <xref ref-type="bibr" rid="bib65">TrinitÃ© et al., 2019</xref>), which was previously shown to be required for CARD8 activation in HIV-1 latently infected cells (<xref ref-type="bibr" rid="bib14">Clark et al., 2022</xref>; <xref ref-type="bibr" rid="bib69">Wang et al., 2021</xref>). However, we observed Gag processing of p55<sup>gag</sup> to p41<sup>gag</sup> and p24<sup>gag</sup> in cytoplasmic lysates of THP-1 cells infected with either WT HIV-1<sub>LAI</sub> or HIV-1<sub>LAI</sub> that was pseudotyped with the vesicular stomatitis virus glycoprotein (VSV-g) instead of its own envelope (HIV-1<sub>LAI-VSVG</sub>), consistent with prior studies demonstrating that some HIV-1<sup>PR</sup> is active in the cytoplasm (<xref ref-type="fig" rid="fig3">Figure 3A</xref>; <xref ref-type="bibr" rid="bib1">Alvarez et al., 2006</xref>; <xref ref-type="bibr" rid="bib64">Tabler et al., 2022</xref>). To determine if CARD8 inflammasome activation can occur during HIV-1 infection in the absence of small molecule-induced HIV-1<sup>PR</sup> dimers, we infected the human leukemia monocytic cell line THP-1 at a multiplicity of infection (MOI) &lt;1 and assayed for cell death (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, left) or IL-1Î² secretion (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, right). As a positive control for inflammasome activity, uninfected cells were also treated with VbP, which specifically activates the CARD8 inflammasome in THP-1 cells (<xref ref-type="bibr" rid="bib28">Johnson et al., 2020</xref>). For both HIV-1-infected and VbP-treated THP-1 cells, we observed an increase in cell death compared to mock-infected controls as measured by uptake of the membrane-impermeable dye propidium iodide (PI) (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, left). However, neither HIV-1 infection nor VbP alone led to an increase in IL-1Î² levels (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, right<bold>,</bold> no prime condition), consistent with prior reports (<xref ref-type="bibr" rid="bib4">Ball et al., 2020</xref>; <xref ref-type="bibr" rid="bib35">Linder et al., 2020</xref>). We reasoned that the lack of cytokine production may either be an intrinsic property of CARD8 (<xref ref-type="bibr" rid="bib4">Ball et al., 2020</xref>) or, alternatively, require a signal (e.g. a TLR agonist) to transcriptionally upregulate or âprimeâ IL-1Î² and/or inflammasome components. Thus, we assessed inflammasome activation by HIV-1 infection or VbP treatment with and without pretreating THP-1 cells with agonists of TLR1/2 (Pam3CSK4), TLR7/8 (CL075), TLR8 (TL8-506), or TLR4 (LPS). We found that VbP treatment and HIV-1<sub>LAI-VSVG</sub> infection induce cell death independent of priming, although TLR agonists did elevate cell death responses in some instances (<xref ref-type="fig" rid="fig3">Figure 3B</xref> left). In contrast, the release of IL-1Î² after HIV-1 infection or VbP treatment was entirely dependent on TLR priming (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, right). Thus, HIV-1 infection alone (i.e. in the absence of molecules causing premature dimerization of Gag-Pol) is sufficient to induce cell death in THP-1 cells, and priming (e.g. via TLR stimulation) is required for HIV-1 infection-induced IL-1Î² secretion and elevated levels of cell death.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>HIV-1 infection activates the CARD8 inflammasome in THP-1 cells.</title><p>(<bold>A</bold>) THP-1 cells were mock infected or infected with HIV-1<sub>LAI</sub> or HIV-1<sub>LAI-VSVG</sub>, yielding 8% and 53% p24<sup>gag</sup>+ cells after 24 hr, respectively. Immunoblotting using cytoplasmic lysates was carried out for HIV protease (HIV<sup>PR</sup>) activity, and vinculin (loading control) as indicated 24 hr post-infection. (<bold>B</bold>) THP-1 cells were either left unprimed or primed with different Toll-like receptor (TLR) agonists 4â6 hr before treatment with 10 ÂµM VbP or infection with HIV-1<sub>LAI-VSVG</sub> at a multiplicity of infection (MOI) such that 30â50% were p24<sup>gag</sup>+ after 24 hr. Inflammasome responses were measured 24 hr following VbP treatment or HIV-1 infection. <italic>Left:</italic> Cell death is reported as the percent of propidium iodide (PI) positive cells. <italic>Right:</italic> Interleukin (IL)-1Î² levels were measured using the IL-1R reporter assay. (<bold>C</bold>) Wildtype (WT), <italic>CARD8</italic> knockout (KO), or caspase-1 (<italic>CASP1</italic>) KO THP-1 lines were primed with Pam3CSK4 then challenged with either HIV-1<sub>LAI</sub> or HIV-1<sub>LAI-VSVG</sub> at an MOI such that 30â50% of WT cells were p24<sup>gag</sup>+ after 24 hr. Subsequent inflammasome activation was assayed 24 hr post-infection. <italic>Left and middle</italic>: Cell death and IL-1Î² levels were measured as in (A). <italic>Right</italic>: Active CASP1 was measured with CASP1-specific FLICA dye. (<bold>D</bold>) WT or <italic>CARD8</italic> KO THP-1s overexpressing CCR5 were primed and treated with 10 ÂµM VbP or infected with HIV-1<sub>BG505</sub> for 24 hr such that ~30% of cells were p24<sup>gag</sup>+ then probed for inflammasome activation via IL-1Î² secretion. HIV-1<sub>BG505</sub> is a CCR5 tropic strain in clade A. The dotted line indicates limit of detection (LoD). Datasets represent mean Â± SD (n=3 biological replicates). p-Values were determined by two-way ANOVA with Dunnettâs (<bold>BâC</bold>) or Sidakâs (<bold>D</bold>) test using GraphPad Prism 9. ns = not significant, *p&lt;0.05,**p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3âsource data 1.</label><caption><title>Tables of source data for propidium iodide uptake, FLICA, and IL-1Î² secretion.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84108-fig3-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84108-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3âfigure supplement 1.</label><caption><title>Functional validation of <italic>CARD8</italic> knockout (KO) THP-1 cells.</title><p>(<bold>A</bold>) Immunoblot of wildtype (WT) or <italic>CARD8</italic> KO THP-1 lines was carried out for CARD8 expression using endogenous antibody against CARD8 C-terminal domain (CTD) and loading control (vinculin). FIIND, function-to-find domain. (<bold>B</bold>) WT or <italic>CARD8</italic> KO THP-1 cells were primed with Pam3CSK4 for 4â6 hr then treated with 10 ÂµM VbP for 24 hr or 5 Âµg/mL nigericin for 3 hr before probing for interleukin (IL)-1Î² secretion (left) or propidium iodide (PI) dye uptake (right). The dotted line indicates limit of detection (LoD). Datasets represent mean Â± SD (n=3 biological replicates). p-Values were determined by two-way ANOVA Sidakâs test using GraphPad Prism 9. ns = not significant, *p&lt;0.05,**p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3âfigure supplement 1âsource data 1.</label><caption><title>Tables of source data for propidium iodide uptake and IL-1Î² secretion.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84108-fig3-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84108-fig3-figsupp1-v2.tif"/></fig></fig-group><p>To determine if inflammasome activation upon HIV-1 infection is dependent on CARD8, we generated clonal THP-1 <italic>CARD8</italic> knockout (KO) cells via CRISPR/Cas9. We confirmed the absence of full-length (~62 kDa) and FIIND-processed (~29 kDa) CARD8 in <italic>CARD8</italic> KO THP-1 cell lines by immunoblotting with an antibody specific to the CARD8 C-terminus (<xref ref-type="fig" rid="fig3s1">Figure 3âfigure supplement 1A</xref>). To functionally test the THP-1 <italic>CARD8</italic> KO cell lines, we primed WT or <italic>CARD8</italic> KO THP-1 cells with Pam3CSK4 then treated with either VbP, which activates the CARD8 inflammasome, or the ionophore nigericin, which specifically activates the NLRP3 inflammasome, and measured cell death and IL-1Î² secretion. As expected, WT but not <italic>CARD8</italic> KO THP-1 cells responded to VbP, whereas both cell lines underwent cell death and IL-1Î² secretion in response to nigericin, indicating that the <italic>CARD8</italic> KO THP-1 cells retained responsiveness to other inflammasome agonists (<xref ref-type="fig" rid="fig3s1">Figure 3âfigure supplement 1B</xref>).</p><p>We next infected both WT, <italic>CARD8</italic> KO, or <italic>CASP1</italic> KO THP-1 cells with WT HIV-1<sub>LAI</sub> or HIV-1<sub>LAI-VSVG</sub> viruses at an MOI that would give 30â50% infection of WT cells. Similar to our observations with VbP, we found that IL-1Î² secretion, cell death, and CASP1 activation (as measured by FLICA assay) were significantly reduced in <italic>CARD8</italic> KO versus WT THP-1 cells following HIV-1 infection (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Because responses to HIV-1 infection were reduced to a similar level in both <italic>CARD8</italic> KO cells and <italic>CASP1</italic> KO cells, our findings suggest that the inflammasome response to HIV-1 infection in THP-1 cells is primarily dependent on CARD8, but independent of HIV-1 envelope. As different HIV-1 and SIV proviruses were found to cleave human CARD8 after transfection in 293T cells (<xref ref-type="fig" rid="fig1">Figure 1</xref> and <xref ref-type="fig" rid="fig2">Figure 2</xref>), we also tested a primary isolate of HIV-1 from a different clade and with a different co-receptor usage (HIV-1<sub>Q23-BG505</sub>, an R5, clade A recombinant virus) in an infection assay in WT and <italic>CARD8</italic> KO THP-1 cells engineered to express the co-receptor CCR5 (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). HIV-1<sub>Q23-BG505</sub> infection also resulted in IL-1Î² secretion in a CARD8-dependent manner, suggesting that CARD8-dependent inflammasome activation is conserved across HIV-1 strains.</p></sec><sec id="s2-4"><title>CARD8-dependent inflammasome activity after HIV-1 infection occurs both early and late in acute infection and depends on the activity of HIV-1<sup>PR</sup></title><p>To gain additional insight into the nature of CARD8 inflammasome responses to HIV-1 infection, we performed a time-course following HIV-1 infection. Unexpectedly, we revealed a statistically significant, CARD8-dependent increase in IL-1Î² as early as 2 hr after infection (the first timepoint assayed after the initial infection), which plateaued for the next 6 hr and then further increased by 24 hr post-infection (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). As the early timepoints were sampled prior to reverse-transcription and the genesis of de novo synthesized HIV-1 transcripts (<xref ref-type="bibr" rid="bib36">Mohammadi et al., 2013</xref>), these findings raised the possibility that CARD8 detects the activity of packaged HIV-1<sup>PR</sup> released into the target cell upon viral entry as well as de novo synthesized Gag-Pol. To test this hypothesis, we treated target cells with the HIV<sup>PR</sup> inhibitor LPV, which blocked CARD8 inflammasome activation by HIV-1 infection, reinforcing that CARD8 senses HIV-1<sup>PR</sup> activity. We also considered the possibility that the packaged viral protein R (Vpr) influences CARD8 inflammasome activation. However, we found that an HIV-1 virus lacking Vpr (ÎVpr) also induces CARD8-dependent inflammasome activation (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Thus, our findings suggest that HIV-1 infection induces inflammasome activation upon CARD8 detection of HIV-1<sup>PR</sup> released from the incoming virion as well as newly translated HIV-1<sup>PR</sup>.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Incoming and outgoing HIV<sup>PR</sup> ar responsible for CARD8 inflammasome activation.</title><p>(<bold>A</bold>) Wildtype (WT), <italic>CARD8</italic> knockout (KO), or caspase-1 (<italic>CASP1</italic>) KO THP-1 cells were primed overnight with Pam3CSK4 and then infected with HIV-1<sub>LAI-VSVG</sub>. Supernatant was collected at 0, 2, 4, 6, 8, and 24 hr post-infection to measure interleukin (IL)-1Î² secretion. Cells were infected at viral concentration such that ~70% of cells were p24<sup>gag</sup>-positive after 24 hr. (<bold>B</bold>) WT THP-1 cells primed with Pam3CSK4 were challenged with WT or mutant HIV-1<sub>LAI-VSVG</sub> or WT virus preincubated in 5 ÂµM lopinavir (LPV) for 30 min prior to infection. HIV-1<sub>LAI-VSVG</sub> ÎVpr has a frameshift mutation in Vpr. Dotted line indicates limit of detection (LoD). Datasets represent mean Â± SD (n=3 biological replicates). p-Values were determined by two-way ANOVA with Dunnettâs test using GraphPad Prism 9. ns = not significant, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4âsource data 1.</label><caption><title>Tables of source data for IL-1Î² secretion.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84108-fig4-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84108-fig4-v2.tif"/></fig></sec><sec id="s2-5"><title>HIV-1 inflammasome activation is dependent on CARD8 sensing of HIV-1<sup>PR</sup> activity</title><p>To further evaluate the role of the human-derived F59-F60 motif of CARD8 after HIV-1 infection, we used a doxycycline (dox)-inducible system to complement <italic>CARD8</italic> KO THP-1 cells with either WT CARD8 or CARD8 cleavage mutants (<xref ref-type="fig" rid="fig5">Figure 5A</xref>) and probed for subsequent inflammasome activation. We found that <italic>CARD8</italic> KO THP-1 cells complemented with WT CARD8 underwent IL-1Î² secretion and cell death in response to both VbP and HIV-1 infection in a dox-dependent manner (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref>), confirming that HIV inflammasome activation is CARD8-dependent. In parallel, we complemented <italic>CARD8</italic> KO THP-1 cells with the CARD8 cleavage mutants F60L, F60S, F60A. All complemented <italic>CARD8</italic> KO THP-1 cells underwent IL-1Î² secretion and cell death in response to VbP in dox-treated cells, demonstrating functional CARD8 expression (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref>). In contrast, infection with both VSV-g pseudotyped (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref>) and replication competent (<xref ref-type="fig" rid="fig5">Figure 5E and F</xref>) HIV-1<sub>LAI</sub> induced IL-1Î² secretion and cell death only in <italic>CARD8</italic> KO THP-1 cells that were complemented with WT human CARD8, but not CARD8 mutants that are resistant to HIV-1<sup>PR</sup> cleavage. We also found that <italic>CARD8</italic> KO THP-1 cells complemented with chimpanzee CARD8 restored responsiveness to VbP but not to HIV-1<sub>LAI</sub> infection, whereas chimpanzee CARD8 L60F (i.e. chimpanzee CARD8 with the phenylalanine at residue 60 as in human CARD8) is cleaved by HIV-1<sup>PR</sup> and SIVcpz<sup>PR</sup> (<xref ref-type="fig" rid="fig5s1">Figure 5âfigure supplement 1</xref>), and can functionally complement human CARD8 responses to HIV-1 infection (<xref ref-type="fig" rid="fig5">Figure 5DâF</xref>). Thus, human CARD8 detects the enzymatic activity of HIV<sup>PR</sup> by encoding a motif that functions as a HIV<sup>PR</sup> substrate, permitting a human-specific CARD8 inflammasome response to HIV-1 infection.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>HIV-1 inflammasome activation is dependent on a human-specific motif in CARD8.</title><p>(<bold>A</bold>) <italic>CARD8</italic> knockout (KO) THP-1 lines complemented with different doxycycline (dox)-inducible CARD8 variants (pCARD8) were left uninduced or induced for 18 hr. Immunoblot of wildtype (WT) or complemented <italic>CARD8</italic> KO THP-1 lines treated with (â+â) or without (âââ) dox was carried out for CARD8 expression using endogenous antibody against CARD8 C-terminal domain (CTD) and loading control (vinculin). FIIND, function-to-find domain. (<bold>BâC</bold>) Complemented <italic>CARD8</italic> KO lines were left uninduced or dox-induced as described in (<bold>A</bold>) and then primed for 4â6 hr with Pam3CSK4 and treated with either 10 ÂµM VbP or HIV-1<sub>LAI-VSVG</sub> then assessed for (<bold>B</bold>) interleukin (IL)-1Î² secretion and (<bold>C</bold>) cell death, respectively. (<bold>D</bold>) <italic>CARD8</italic> KO THP-1 lines complemented with different CARD8 variants were left uninduced or induced for 18 hr. Immunoblot of wildtype (WT) or complemented <italic>CARD8</italic> KO THP-1 lines treated with (â+â) or without (âââ) dox as described in (A). (<bold>EâF</bold>) Complemented <italic>CARD8</italic> KO lines were induced and primed as described in (B) then treated with either 10 ÂµM VbP or HIV-1<sub>LAI</sub> then assessed for (<bold>E</bold>) IL-1Î² secretion and (<bold>F</bold>) cell death, respectively. All HIV infections were done at a multiplicity of infection (MOI) such that 30â50% of cells were p24<sup>gag</sup>+ after 24 hr. Dotted line indicates limit of detection (LoD). Datasets represent mean Â± SD (n=3 biological replicates). p-Values were determined by two-way ANOVA with Tukeyâs test using GraphPad Prism 9. ns = not significant, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5âsource data 1.</label><caption><title>Tables of source data for propidium iodide uptake and IL-1Î² secretion.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84108-fig5-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84108-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5âfigure supplement 1.</label><caption><title>Human FF motif in chimpanzee CARD8 rescues sensing of HIV/SIV<sup>PR</sup>.</title><p>HEK293T cells were transfected with a construct encoding N-terminally mCherry-tagged human, chimpanzee (cpz), or cpz with the human FF motif (L60F) CARD8 and indicated provirus constructs. Immunoblotting was carried out for CARD8 cleavage, HIV/SIV protease (S/HIV<sup>PR</sup>) activity, and vinculin (loading control) as indicated. The S/HIV<sup>PR</sup> cleavage product is indicated by a purple triangle. FIIND, function-to-find domain.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84108-fig5-figsupp1-v2.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The ability to selectively induce CARD8-dependent pyroptosis in HIV-1 latently infected CD4+ T cells via NNRTI-enforced dimerization of HIV-1<sup>PR</sup> has garnered much interest as a means to clear the latent reservoir (<xref ref-type="bibr" rid="bib3">Balibar et al., 2023</xref>; <xref ref-type="bibr" rid="bib14">Clark et al., 2022</xref>; <xref ref-type="bibr" rid="bib39">Moore et al., 2022</xref>; <xref ref-type="bibr" rid="bib61">Sparrer and Kirchhoff, 2021</xref>). Here, we demonstrate that CARD8 also senses HIV-1 replication in acutely infected cells, which occurs following HIV-1<sup>PR</sup> site-specific cleavage of a human-specific motif in the CARD8 tripwire. We further show that the unique motif in human CARD8, which is not present in other sampled hominoids and Old World monkeys, enables its sensing of SIVcpz<sup>PR</sup> â the precursor to HIV-1, indicating that the precursor viruses to HIV-1 were poised to cleave human CARD8 prior to spillover into humans. These results, along with other recent findings (<xref ref-type="bibr" rid="bib42">Nadkarni et al., 2022</xref>; <xref ref-type="bibr" rid="bib68">Tsu et al., 2023</xref>), demonstrate that CARD8 is a bone fide innate immune sensor of viral infection via sensing viral protease activity, and suggest a model for a human-specific inflammatory response to HIV infection.</p><sec id="s3-1"><title>CARD8 as an innate immune sensor of HIV-1<sup>PR</sup> activity</title><p>Some positive-sense RNA viruses that do not package their viral proteases are sensed following de novo synthesized viral protease (<xref ref-type="bibr" rid="bib42">Nadkarni et al., 2022</xref>; <xref ref-type="bibr" rid="bib68">Tsu et al., 2023</xref>). However, as HIV-1 triggers CARD8 inflammasome activation as early as 2 hr post-infection, well before de novo synthesis of viral proteins (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), our findings suggest that HIV-1 entry is also targeted by CARD8 via the innate immune detection of incoming viral protease activity. This conclusion is supported by a recent report that also found that HIV-1 strains lacking RT or integrase function are still sensed by the CARD8 inflammasome in a manner dependent on HIV-1<sup>PR</sup> activity (<xref ref-type="bibr" rid="bib70">Wang and Shan, 2023</xref>). Based on these findings, we propose that CARD8 can sense HIV-1<sup>PR</sup> that is packaged into the virion upon its release into the host cytosol upon viral fusion. This idea is consistent with reports that HIV-1<sup>PR</sup> can function intracellularly to cleave host targets, and not solely in the context of Gag-Pol dimerization during virion assembly and maturation (<xref ref-type="bibr" rid="bib1">Alvarez et al., 2006</xref>; <xref ref-type="bibr" rid="bib64">Tabler et al., 2022</xref>). We speculate that for HIV-1 this may be particularly relevant for cell-to-cell infection. Thus, our present findings, along with other recent examples of innate immune detection of viral protease activity (<xref ref-type="bibr" rid="bib42">Nadkarni et al., 2022</xref>; <xref ref-type="bibr" rid="bib68">Tsu et al., 2023</xref>), suggest that CARD8âs broad antiviral sensing capacity is predicated on its detection of the ubiquitous and essential function of viral proteases, which are evolutionarily constrained by their requirement to target both viral polyprotein and host targets.</p><p>We find that inflammasome responses downstream of CARD8 are modulated by TLR stimulation. For example, CARD8-dependent cell death is modestly enhanced by TLR priming by an unknown mechanism (<xref ref-type="fig" rid="fig3">Figure 3</xref>). On the other hand, IL-1Î² secretion following HIV-1 infection is strictly dependent on TLR priming, consistent with its established role for transcriptional upregulation of IL-1Î² (<xref ref-type="bibr" rid="bib12">Chan and Schroder, 2019</xref>). These findings may offer a potential explanation for conflicting reports as to whether or not primary CD4+ T cells undergo pyroptosis and induce IL-1Î² secretion in response to HIV-1 infection (<xref ref-type="bibr" rid="bib16">Doitsh et al., 2014</xref>; <xref ref-type="bibr" rid="bib41">MuÃ±oz-Arias et al., 2015</xref>). Our findings that several TLR agonists effectively prime CARD8 inflammasome responses (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref>) suggest that HIV-1 pathogen-associated molecular patterns (i.e. viral nucleic acids) and/or circulating microbial ligands from gut epithelial breakdown, a hallmark of acute HIV-1 disease (<xref ref-type="bibr" rid="bib53">Sandler and Douek, 2012</xref>), are potential sources for priming of HIV-1 target cells in vivo. Moreover, given the exciting potential of combinatorial host- and virus-directed strategies of HIV-1 reservoir clearance by lowering CARD8 activation threshold (via VbP) and enforced HIV<sup>PR</sup> cytosolic activity (<xref ref-type="bibr" rid="bib3">Balibar et al., 2023</xref>), our findings may also guide therapeutic strategies that leverage HIV<sup>PR</sup>-dependent CARD8 inflammasome activation, which may be bolstered by adjuvants that induce TLR signaling (<xref ref-type="bibr" rid="bib32">Kim and Shan, 2022</xref>; <xref ref-type="bibr" rid="bib39">Moore et al., 2022</xref>; <xref ref-type="bibr" rid="bib69">Wang et al., 2021</xref>).</p></sec><sec id="s3-2"><title>Human CARD8 as a maladaptation to HIV-1 infection</title><p>Several adaptations of SIVcpz have occurred following its spillover in humans, including Vpu antagonism of human tetherin/Bst2 (<xref ref-type="bibr" rid="bib34">Lim et al., 2010</xref>; <xref ref-type="bibr" rid="bib55">Sauter et al., 2009</xref>), a mutation in MA that allows infection of human tissues (<xref ref-type="bibr" rid="bib7">Bibollet-Ruche et al., 2012</xref>), and the adaptation of Vif to antagonize one of the human polymorphisms in APOBEC3H (<xref ref-type="bibr" rid="bib71">Zhang et al., 2017</xref>). However, other host-virus interactions important for permitting the establishment of the HIV/AIDS (acquired immunodeficiency syndrome) pandemic, such as that of SIVcpz Vif with APOBEC3G, arose in intermediate hosts where no further adaptations were required for passage to humans (<xref ref-type="bibr" rid="bib8">Binning et al., 2019</xref>; <xref ref-type="bibr" rid="bib18">Etienne et al., 2013</xref>). Our findings suggest that the interaction of HIV-1<sup>PR</sup> with human CARD8 is distinct from these scenarios, as SIVcpz<sup>PR</sup> already had the capacity to cleave human CARD8 before its cross-species transmission to humans, despite the fact that chimpanzee CARD8 is not itself cleaved by SIVcpz<sup>PR</sup> due to the lack of the FF motif at amino acid 59/60 (<xref ref-type="fig" rid="fig1">Figures 1</xref> and <xref ref-type="fig" rid="fig2">2</xref>).</p><p>The F59-F60 motif that confers human CARD8 with the unique capacity to sense HIV/SIVcpz<sup>PR</sup> is conserved across all humans based on publicly available datasets, as well as being present in a Neanderthal genome, suggesting a genetic sweep occurred in favor of a phenylalanine at position 60. HIV-1 emerged within the past century (<xref ref-type="bibr" rid="bib59">Sharp and Hahn, 2010</xref>) and therefore could not have driven the evolution of the HIV-1<sup>PR</sup> cleavage site in human CARD8. However, human <italic>CARD8</italic> is highly polymorphic, and multiple residues of the N-terminus of CARD8, including those that allow CARD8 sensing of extant human pathogenic viruses including coronaviruses and picornaviruses, show strong evidence of positive selection, an evolutionary signature consistent with a history of host-pathogen conflict (<xref ref-type="bibr" rid="bib15">Daugherty and Malik, 2012</xref>; <xref ref-type="bibr" rid="bib68">Tsu et al., 2023</xref>). Indeed, the HIV-1<sup>PR</sup> cleavage site in CARD8 overlaps with a site that is cleaved by the coronavirus 3CL protease (<xref ref-type="bibr" rid="bib68">Tsu et al., 2023</xref>). Although it is possible that the human-specific F60 was fixed stochastically or as a passenger mutation, we favor a scenario in which human CARD8 sensing of HIV-1<sup>PR</sup> arose as a consequence of CARD8 adaptation to another virus (<xref ref-type="bibr" rid="bib42">Nadkarni et al., 2022</xref>; <xref ref-type="bibr" rid="bib68">Tsu et al., 2023</xref>). Thus, we speculate that an ancient infection of our human ancestors may be responsible for our modern-day maladaptation to HIV-1.</p></sec><sec id="s3-3"><title>Possible links to pathogenesis</title><p>HIV-1 disease progression to AIDS is characterized by dramatic depletion of CD4+ T cells including via pyroptosis (<xref ref-type="bibr" rid="bib16">Doitsh et al., 2014</xref>) and chronic inflammation accompanied by high levels of plasma cytokines including IL-1 (<xref ref-type="bibr" rid="bib2">Arditi et al., 1991</xref>; <xref ref-type="bibr" rid="bib40">Muema et al., 2020</xref>). As such, multiple inflammasomes have previously been implicated for HIV-dependent inflammasome activation, although the exact mechanisms have remained unclear (<xref ref-type="bibr" rid="bib37">Monroe et al., 2014</xref>; <xref ref-type="bibr" rid="bib72">Zhang et al., 2021</xref>). Here, we show that HIV infection induces pyroptotic cell death and IL-1Î² secretion via CARD8 recognition of HIV<sup>PR</sup> activity. Our finding that HIV-1 infection is sufficient to induce inflammasome activation, along with the presence of CARD8 in relevant T cell populations (<xref ref-type="bibr" rid="bib14">Clark et al., 2022</xref>; <xref ref-type="bibr" rid="bib28">Johnson et al., 2020</xref>; <xref ref-type="bibr" rid="bib35">Linder et al., 2020</xref>), also suggests that CARD8 contributes to HIV pathogenesis. Consistent with this hypothesis, recent publications show that HIV-1 infection drives CARD8-dependent pyroptotic cell death both in primary human CD4+ T cells ex vivo and in humanized mouse models of HIV-1 (<xref ref-type="bibr" rid="bib70">Wang and Shan, 2023</xref>). It is also possible that IL-1Î² release after HIV-1-dependent CARD8 activation after HIV-1 infection could contribute to pathogenesis since IL-1Î² induces the differentiation of Th17 cells (<xref ref-type="bibr" rid="bib13">Chung et al., 2009</xref>), a highly HIV-susceptible CD4+ T cell subtype, as well as the recruitment of other target immune cells (<xref ref-type="bibr" rid="bib50">Rider et al., 2011</xref>).</p><p>SIVs are believed to be generally non-pathogenic in their reservoir hosts with the SIVsmm in sooty mangabeys and SIVagm in African green monkeys as the best studied examples (<xref ref-type="bibr" rid="bib26">Jasinska et al., 2023</xref>). SIVcpz in naturally infected chimpanzees is pathogenic although not to the extent of HIV-1 group M infection of untreated humans (<xref ref-type="bibr" rid="bib31">Keele et al., 2009</xref>). In contrast, SIVs can cause disease in a new species, including experimental SIV infections of macaque monkeys. It is tempting to speculate that these species-specific differences could be, in part, mediated by differential CARD8 inflammasome activation, which in turn influences the extent of CD4+ T cell depletion, chronic immune activation, and bystander cell immunopathology â key pathogenic events that drive the progression to AIDS in the absence of antiretroviral therapy (<xref ref-type="bibr" rid="bib29">Kaur et al., 1998</xref>; <xref ref-type="bibr" rid="bib31">Keele et al., 2009</xref>; <xref ref-type="bibr" rid="bib44">Paiardini and MÃ¼ller-Trutwin, 2013</xref>). Although our data demonstrates that functional HIV and SIVcpz protease recognition motifs outside of the F59-F60 are absent in human and chimpanzee CARD8, it remains possible that other SIVs have distinct protease specificities that allow for cleavage of species-specific recognition motifs in CARD8 in non-human primates. Indeed, the substrate specificity of SIVmac239<sup>PR</sup> is distinct from HIV-1<sup>PR</sup> (<xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref>), which may be relevant to CARD8 inflammasome activation and CD4+ T cell depletion in experimental macaque infections. We suggest that future work determining these host- and virus-specific interactions is an important consideration when evaluating HIV pathogenesis in non-human primate models.</p></sec></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Plasmids</title><p>psPAX2 and pMD2.G were gifts from Didier Trono (Addgene). The dox-inducible pLKO-puro vector (<xref ref-type="bibr" rid="bib10">Busnadiego et al., 2014</xref>) was a gift from Melissa Kane. Infectious molecular clones for SIVcpz<sub>EK505</sub> and SIVcpz<sub>LB715</sub> were gifts from Beatrice Hahn (<xref ref-type="bibr" rid="bib5">Barbian et al., 2015</xref>; <xref ref-type="bibr" rid="bib30">Keele et al., 2006</xref>). HIV-1<sub>Q23</sub> Îenv provirus and the HIV-1<sub>Q23.BG505</sub> proviruses were gifts from Julie Overbaugh (<xref ref-type="bibr" rid="bib24">Haddox et al., 2018</xref>; <xref ref-type="bibr" rid="bib48">Poss and Overbaugh, 1999</xref>). HIV-1<sub>LAI</sub> and HIV-2<sub>Rod</sub> were previously described (<xref ref-type="bibr" rid="bib23">Guyader et al., 1987</xref>; <xref ref-type="bibr" rid="bib46">Peden et al., 1991</xref>). The HIV-1<sub>LAI</sub>ÎVpr mutant has a frameshift mutation that inactivates the <italic>vpr</italic> gene as described (<xref ref-type="bibr" rid="bib52">Rogel et al., 1995</xref>). CARD8 sequence IDs used for phylogenetic analysis in <xref ref-type="fig" rid="fig1">Figure 1A</xref> can be found in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1c</xref>. For CARD8 cleavage assays, the coding sequences of human CARD8 (NCBI accession NP_001171829.1) and chimpanzee CARD8 (NCBI accession XM_024351500.1) were cloned into the pcDNA3.1 backbone (Addgene) with an N-terminal mCherry tag using BamHI and EcoRI cut sites. For dox-inducible complementation assays, the coding sequences of human and chimpanzee CARD8 were cloned into the pLKO-puro backbone using the Sfil site. Point mutations were introduced using overlapping PCR. Full list of primer sequences can be found in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>.</p></sec><sec id="s4-2"><title>Cell culture</title><p>THP-1 cells (ATCC) were cultured in RPMI (Invitrogen) with 10% FBS, 1% penicillin/streptomycin antibiotics, 10 mM HEPES, 0.11 g/L sodium pyruvate, 4.5 g/L D-glucose and 1% Glutamax. HEK 293T (ATCC) were cultured in DMEM (Invitrogen) with 10% FBS and 1% penicillin/streptomycin antibiotics. All puromycin selections were done at 0.5 Âµg/mL. For complemented dox-inducible lines, tetracycline-free FBS (Sigma) was used to prevent background CARD8 expression. All lines routinely tested negative for mycoplasma bacteria (Fred Hutch Specimen Processing &amp; Research Cell Bank).</p></sec><sec id="s4-3"><title>Immunoblotting</title><p>Cells were washed once with 1Ã PBS before harvesting in NP-40 buffer with protease inhibitor (200 mM NaCl, 50 mM Tris pH 7.4, 0.5% NP-40 alternative, 1 mM dithiothreitol, and Roche Complete Mini, EDTA-free tablets; catalog no. 11836170001). Cytoplasmic lysates were clarified via centrifugation and combined with 4Ã NuPage LDS Sample Buffer (Invitrogen) containing 10% Î²-mercaptoethanol and boiled for 5â10 min. Samples were run on a 4â12% SDS-PAGE gel using morpholineethanesulfonic acid buffer, transferred to a nitrocellulose membrane using a Pierce G2 Fast Blotter (Thermo Scientific), blocked in 5% nonfat milk then probed for with primary antibodies diluted in 2.5% milk for mCherry (for CARD8 cleavage), p24<sup>gag</sup> (for HIV<sup>PR</sup> activity), CARD8 C-terminus (for KO validation and complementation), and vinculin (loading control). Blots were washed three times with PBS-T (0.1% Tween-20), incubated with secondary HRP-conjugated antibodies, washed three times again, and then developed with SuperSignal West Femto Maximum Sensitivity Substrate (Fisher Scientific). Further antibody specifications/concentrations and clone info are described in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>.</p></sec><sec id="s4-4"><title>CARD8 cleavage assay</title><p>HEK293T cells were seeded at 1.5â2 Ã 10<sup>5</sup> cells/well in 24-well plates the day before transfection using TransIT-LT1 reagent at 1.5 ÂµL transfection reagent/well (Mirus Bio LLC). One hundred ng of indicated constructs encoding an N-terminal mCherry-tagged CARD8 were co-transfected into HEK293T cells with either 400 ng of pcDNA3.1 empty vector (âââ) or 400 ng of HIV provirus or SIVcpz provirus. HIV Îenv proviruses were used for immunoblots in <xref ref-type="fig" rid="fig1">Figure 1</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref>, while infectious HIV and SIVcpz provirus were used for immunoblots in <xref ref-type="fig" rid="fig2">Figure 2</xref>. Cytoplasmic lysates were harvested 24 hr post-transfection and immunoblotted as described above.</p></sec><sec id="s4-5"><title>FLICA assay</title><p>Live cells were incubated in media containing FLICA dye (Immunochemistry Technologies, cat. #97) at a dilution of 1:60-1:100 for 30 min at 37Â°C then washed and fixed according to the manufacturerâs protocol. Stained cells were flowed for analysis on a BD Celesta within 18 hr post-staining.</p></sec><sec id="s4-6"><title><italic>CARD8 and CASP1</italic> KO generation</title><p><italic>CARD8</italic> and <italic>CASP1</italic> KO THP-1 cells were generated similarly to <italic>NLRP1</italic> KO described previously (<xref ref-type="bibr" rid="bib66">Tsu et al., 2021a</xref>). Briefly, a <italic>CARD8</italic> or <italic>CASP1</italic>-specific sgRNA was designed using CHOPCHOP (<xref ref-type="bibr" rid="bib33">Labun et al., 2019</xref>), and cloned into a plasmid containing U6-sgRNA-CMV-mCherry-T2A-Cas9 using ligation-independent cloning. THP-1 cells were electroporated using the Bio-Rad Gene Pulser Xcell. After 24 hr, mCherry-positive cells were sorted and plated for cloning by limiting dilution. Monoclonal lines were validated as KO by deep sequencing and OutKnocker analysis, as described previously (<xref ref-type="bibr" rid="bib56">Schmid-Burgk et al., 2014</xref>; <xref ref-type="bibr" rid="bib57">Schmidt et al., 2016</xref>). KO lines were further validated by immunoblot and functional assays. sgRNA used to generate KO are described in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>.</p></sec><sec id="s4-7"><title>CCR5+ cell line generation</title><p>WT or <italic>CARD8</italic> KO THP-1 cells were transduced with pHIV-CCR5/ZsGreen as previously described (<xref ref-type="bibr" rid="bib38">Montoya et al., 2023</xref>). Cells were sorted 4 days post-transduction on a Sony MA900.</p></sec><sec id="s4-8"><title>CARD8 complementation</title><p>HEK293T were seeded at 2Ã10<sup>5</sup> cells/well in six-well plates the day before transfection using TransIT-LT1 reagent (Mirus Bio LLC) at 5.8 ÂµL transfection reagent/well. Cells were co-transfected with pLKO-CARD8, psPAX2, and pMD2.G and media was replaced the next day. Virus was harvested 2 days post-transfection and underwent one freeze thaw cycle at â80Â°C before transducing <italic>CARD8</italic> KO THP-1 cells. <italic>CARD8</italic> KO THP-1 cells were seeded at 2Ã10<sup>5</sup> cells/well in six-well plates and transduced with 800 ÂµL virus in the presence of 1 Âµg/mL polybrene via spinoculation at 1100 Ã <italic>g</italic> for 30 min at 30Â°C then puro-selected 24 hr post-transduction.</p></sec><sec id="s4-9"><title>HIV-1<sub>LAI</sub>, HIV-1<sub>Q23-BG505</sub>, and HIV-1<sub>LAI-VSVG</sub> production</title><p>293T cells were seeded at 2Ã10<sup>5</sup> cells/well in six-well plates the day before transfection using TransIT-LT1 reagent (Mirus Bio LLC) at 3 ÂµL transfection reagent/well as previously described (<xref ref-type="bibr" rid="bib43">OhAinle et al., 2018</xref>). For HIV-1 production, 293Ts were transfected with either 1 Âµg/well HIV<sub>LAI</sub> proviral DNA or 1 Âµg/well HIV<sub>LAI</sub> Îenv DNA and 500 ng/well pMD2.G for HIV-1<sub>LAI</sub> and HIV-1<sub>LAI-VSVG</sub>, respectively. One day post-transfection, media was replaced. Two or three days post-transfection, viral supernatants were collected and filtered through a 20 Î¼m filter and aliquots were frozen at â80Â°C. HIV-1<sub>LAI</sub> and HIV-1<sub>LAI-VSVG</sub> proviruses were previously described (<xref ref-type="bibr" rid="bib6">Bartz and Vodicka, 1997</xref>; <xref ref-type="bibr" rid="bib22">Gummuluru et al., 2003</xref>; <xref ref-type="bibr" rid="bib46">Peden et al., 1991</xref>). HIV-1<sub>Q23-BG505</sub> was produced in the same way as HIV-1<sub>LAI</sub>.</p></sec><sec id="s4-10"><title>THP-1 priming and HIV-1 infection</title><p>THP-1 cells were seeded at 1Ã10<sup>5</sup> cells/well in 96-well U-bottom plates in media containing TLR agonist (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>) for 4â6 hr or overnight then treated with either Val-boroPro (10 ÂµM) or nigericin (5 Âµg/mL) or infected with HIV-1<sub>LAI</sub>, HIV-1<sub>Q23-BG505</sub>, or HIV-1<sub>LAI-VSVG</sub> in the presence of 20 Âµg/mL DEAE-Dextran via spinoculation at 1100 Ã <italic>g</italic> for 30 min at 30Â°C. All infections were done at an MOI &lt;1. 24 hr post-infection or VbP treatment (2 hr for nigericin), supernatants were collected for IL-1Î² quantification (see IL-1R reporter assay), and cells were stained with PI or FLICA dye then fixed and stained with p24<sup>gag</sup>-FITC for flow cytometry.</p></sec><sec id="s4-11"><title>IL-1R reporter assay</title><p>To quantify the IL-1Î² secretion, HEK-Blue IL-1Î² reporter cells (Invivogen) were used whereby binding of IL-1Î² to the surface receptor IL-1R1 results in the downstream activation of NF-kB and subsequent production of secreted embryonic alkaline phosphatase (SEAP) in a dose-dependent manner as previously described (<xref ref-type="bibr" rid="bib66">Tsu et al., 2021a</xref>). SEAP levels were detected using a colorimetric substrate assay, QUANTI-Blue (Invivogen), by measuring an increase in absorbance at OD655. Culture supernatant from treated or infected THP-1 cells was transferred to HEK-Blue IL-1Î² reporter cells plated in 96-well format in a total volume of 200 ÂµL per well at 5Ã10<sup>5</sup> cells/well. On the same plate, serial dilutions of recombinant human IL-1Î² (Peprotech) were added to generate a standard curve for each assay. After 24 hr, SEAP levels were assayed by adding 50 ÂµL of the supernatant from HEK-Blue IL-1Î² reporter cells to 150 ÂµL of QUANTI-Blue colorimetric substrate along with 0.25% Tween-20 to neutralize HIV virions in supernatant before readout. After incubation at 37Â°C for 15â30 min, absorbance at OD655 was measured on an Epoch Microplate Spectrophotometer (BioTek) and absolute levels of IL-1Î² were calculated relative to the standard curve.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing â original draft, Writing â review and editing</p></fn><fn fn-type="con" id="con2"><p>Resources, Methodology, Writing â review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Visualization, Methodology, Writing â original draft, Writing â review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing â original draft, Writing â review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Primers, reagents, and primate CARD8 sequence info.</title><p>(a) List of primers, gBlocks, and sgRNA sequences. (b) List of antibodies/reagents. (c) Primate CARD8 gene IDs.</p></caption><media xlink:href="elife-84108-supp1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-84108-mdarchecklist1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Uncropped western blots tiffs from <xref ref-type="fig" rid="fig1">Figures 1</xref>â<xref ref-type="fig" rid="fig5">5</xref>.</title></caption><media xlink:href="elife-84108-data1-v2.zip" mimetype="application" mime-subtype="zip"/></supplementary-material><supplementary-material id="sdata2"><label>Source data 2.</label><caption><title>Uncropped western blots pdf from <xref ref-type="fig" rid="fig1">Figures 1</xref>â<xref ref-type="fig" rid="fig5">5</xref> .</title></caption><media xlink:href="elife-84108-data2-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="sdata3"><label>Source data 3.</label><caption><title>Uncropped western blots pdf from <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3âfigure supplement 1</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5âfigure supplement 1</xref>.</title></caption><media xlink:href="elife-84108-data3-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analyzed during this study are included as source data files in the article.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank everyone in the Emerman and Mitchell labs, Amandine Chantharath for assistance with cloning, Abby Felton for assistance with cell sorting, Joy Twentyman for assistance with cell maintenance, Matt Daugherty, Emily Hsieh, and Brian Tsu for critical reading of the manuscript, Janet Young for helpful discussions, Melissa Kane for kindly providing the dox-inducible plasmid (pLKO-puro) used for complementation experiments, Liang Shan and his lab members for discussions and sharing of unpublished results, and the Fred Hutchinson Shared Resources Genomics, Flow Cytometry, and Specimen Processing &amp; Research Cell Bank cores. LPV (HRP-9481) and p24<sup>gag</sup> antibody (ARP-3537) were provided by the AIDS Reagent Program, Division of AIDS, NIAID, NIH. This work was supported by grants from the National Institutes of Health (NIH) (DP2 AI 154432-01) and the Mallinckrodt Foundation to PSM; NIH grants DP1 DA051110-03 to ME, and University of Washington Cellular and Molecular Biology Training Grant (T32 GM007270) to JK.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez</surname><given-names>E</given-names></name><name><surname>CastellÃ³</surname><given-names>A</given-names></name><name><surname>MenÃ©ndez-Arias</surname><given-names>L</given-names></name><name><surname>Carrasco</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>HIV protease cleaves Poly(A)-Binding protein</article-title><source>The Biochemical Journal</source><volume>396</volume><fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1042/BJ20060108</pub-id><pub-id pub-id-type="pmid">16594896</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arditi</surname><given-names>M</given-names></name><name><surname>Kabat</surname><given-names>W</given-names></name><name><surname>Yogev</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Serum tumor necrosis factor alpha, interleukin 1-beta, P24 antigen concentrations and Cd4+ cells at various stages of human immunodeficiency virus 1 infection in children</article-title><source>The Pediatric Infectious Disease Journal</source><volume>10</volume><fpage>450</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1097/00006454-199106000-00007</pub-id><pub-id pub-id-type="pmid">1677177</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balibar</surname><given-names>CJ</given-names></name><name><surname>Klein</surname><given-names>DJ</given-names></name><name><surname>Zamlynny</surname><given-names>B</given-names></name><name><surname>Diamond</surname><given-names>TL</given-names></name><name><surname>Fang</surname><given-names>Z</given-names></name><name><surname>Cheney</surname><given-names>CA</given-names></name><name><surname>Kristoff</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Bukhtiyarova</surname><given-names>M</given-names></name><name><surname>Ou</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Ba</surname><given-names>L</given-names></name><name><surname>Carroll</surname><given-names>SS</given-names></name><name><surname>El Marrouni</surname><given-names>A</given-names></name><name><surname>Fay</surname><given-names>JF</given-names></name><name><surname>Forster</surname><given-names>A</given-names></name><name><surname>Goh</surname><given-names>SL</given-names></name><name><surname>Gu</surname><given-names>M</given-names></name><name><surname>Krosky</surname><given-names>D</given-names></name><name><surname>Rosenbloom</surname><given-names>DIS</given-names></name><name><surname>Sheth</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Zebisch</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>T</given-names></name><name><surname>Zuck</surname><given-names>P</given-names></name><name><surname>Grobler</surname><given-names>J</given-names></name><name><surname>Hazuda</surname><given-names>DJ</given-names></name><name><surname>Howell</surname><given-names>BJ</given-names></name><name><surname>Converso</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Potent targeted activator of cell kill molecules eliminate cells expressing HIV-1</article-title><source>Science Translational Medicine</source><volume>15</volume><elocation-id>eabn2038</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abn2038</pub-id><pub-id pub-id-type="pmid">36812345</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ball</surname><given-names>DP</given-names></name><name><surname>Taabazuing</surname><given-names>CY</given-names></name><name><surname>Griswold</surname><given-names>AR</given-names></name><name><surname>Orth</surname><given-names>EL</given-names></name><name><surname>Rao</surname><given-names>SD</given-names></name><name><surname>Kotliar</surname><given-names>IB</given-names></name><name><surname>Vostal</surname><given-names>LE</given-names></name><name><surname>Johnson</surname><given-names>DC</given-names></name><name><surname>Bachovchin</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Caspase-1 Interdomain Linker cleavage is required for Pyroptosis</article-title><source>Life Science Alliance</source><volume>3</volume><elocation-id>e202000664</elocation-id><pub-id pub-id-type="doi">10.26508/lsa.202000664</pub-id><pub-id pub-id-type="pmid">32051255</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbian</surname><given-names>HJ</given-names></name><name><surname>Decker</surname><given-names>JM</given-names></name><name><surname>Bibollet-Ruche</surname><given-names>F</given-names></name><name><surname>Galimidi</surname><given-names>RP</given-names></name><name><surname>West</surname><given-names>AP</given-names></name><name><surname>Learn</surname><given-names>GH</given-names></name><name><surname>Parrish</surname><given-names>NF</given-names></name><name><surname>Iyer</surname><given-names>SS</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Pace</surname><given-names>CS</given-names></name><name><surname>Song</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Denny</surname><given-names>TN</given-names></name><name><surname>Mouquet</surname><given-names>H</given-names></name><name><surname>Martin</surname><given-names>L</given-names></name><name><surname>Acharya</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Verrips</surname><given-names>CT</given-names></name><name><surname>Strokappe</surname><given-names>NM</given-names></name><name><surname>Rutten</surname><given-names>L</given-names></name><name><surname>McCoy</surname><given-names>LE</given-names></name><name><surname>Weiss</surname><given-names>RA</given-names></name><name><surname>Brown</surname><given-names>CS</given-names></name><name><surname>Jackson</surname><given-names>R</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name><name><surname>Connors</surname><given-names>M</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Ho</surname><given-names>DD</given-names></name><name><surname>Farzan</surname><given-names>M</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Neutralization properties of Simian immunodeficiency viruses infecting chimpanzees and Gorillas</article-title><source>mBio</source><volume>6</volume><elocation-id>e00296-15</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.00296-15</pub-id><pub-id pub-id-type="pmid">25900654</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartz</surname><given-names>SR</given-names></name><name><surname>Vodicka</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Production of high-titer human immunodeficiency virus type 1 Pseudotyped with vesicular Stomatitis virus glycoprotein</article-title><source>Methods</source><volume>12</volume><fpage>337</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1006/meth.1997.0487</pub-id><pub-id pub-id-type="pmid">9245614</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bibollet-Ruche</surname><given-names>F</given-names></name><name><surname>Heigele</surname><given-names>A</given-names></name><name><surname>Keele</surname><given-names>BF</given-names></name><name><surname>Easlick</surname><given-names>JL</given-names></name><name><surname>Decker</surname><given-names>JM</given-names></name><name><surname>Takehisa</surname><given-names>J</given-names></name><name><surname>Learn</surname><given-names>G</given-names></name><name><surname>Sharp</surname><given-names>PM</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name><name><surname>Kirchhoff</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Efficient Sivcpz replication in human Lymphoid tissue requires viral matrix protein adaptation</article-title><source>The Journal of Clinical Investigation</source><volume>122</volume><fpage>1644</fpage><lpage>1652</lpage><pub-id pub-id-type="doi">10.1172/JCI61429</pub-id><pub-id pub-id-type="pmid">22505456</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Binning</surname><given-names>JM</given-names></name><name><surname>Chesarino</surname><given-names>NM</given-names></name><name><surname>Emerman</surname><given-names>M</given-names></name><name><surname>Gross</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Structural basis for a species-specific determinant of an SIV Vif protein toward Hominid Apobec3G antagonism</article-title><source>Cell Host &amp; Microbe</source><volume>26</volume><fpage>739</fpage><lpage>747</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2019.10.014</pub-id><pub-id pub-id-type="pmid">31830442</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broz</surname><given-names>P</given-names></name><name><surname>Dixit</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Inflammasomes: mechanism of assembly, regulation and signalling</article-title><source>Nature Reviews. Immunology</source><volume>16</volume><fpage>407</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1038/nri.2016.58</pub-id><pub-id pub-id-type="pmid">27291964</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busnadiego</surname><given-names>I</given-names></name><name><surname>Kane</surname><given-names>M</given-names></name><name><surname>Rihn</surname><given-names>SJ</given-names></name><name><surname>Preugschas</surname><given-names>HF</given-names></name><name><surname>Hughes</surname><given-names>J</given-names></name><name><surname>Blanco-Melo</surname><given-names>D</given-names></name><name><surname>Strouvelle</surname><given-names>VP</given-names></name><name><surname>Zang</surname><given-names>TM</given-names></name><name><surname>Willett</surname><given-names>BJ</given-names></name><name><surname>Boutell</surname><given-names>C</given-names></name><name><surname>Bieniasz</surname><given-names>PD</given-names></name><name><surname>Wilson</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Host and viral determinants of Mx2 antiretroviral activity</article-title><source>Journal of Virology</source><volume>88</volume><fpage>7738</fpage><lpage>7752</lpage><pub-id pub-id-type="doi">10.1128/JVI.00214-14</pub-id><pub-id pub-id-type="pmid">24760893</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castro</surname><given-names>LK</given-names></name><name><surname>Daugherty</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Tripping the wire: sensing of viral protease activity by Card8 and Nlrp1 Inflammasomes</article-title><source>Current Opinion in Immunology</source><volume>83</volume><elocation-id>102354</elocation-id><pub-id pub-id-type="doi">10.1016/j.coi.2023.102354</pub-id><pub-id pub-id-type="pmid">37311351</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>AH</given-names></name><name><surname>Schroder</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Inflammasome signaling and regulation of Interleukin-1 family Cytokines</article-title><source>The Journal of Experimental Medicine</source><volume>217</volume><elocation-id>e20190314</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20190314</pub-id><pub-id pub-id-type="pmid">31611248</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>SH</given-names></name><name><surname>Martinez</surname><given-names>GJ</given-names></name><name><surname>Yang</surname><given-names>XO</given-names></name><name><surname>Nurieva</surname><given-names>R</given-names></name><name><surname>Kang</surname><given-names>HS</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Watowich</surname><given-names>SS</given-names></name><name><surname>Jetten</surname><given-names>AM</given-names></name><name><surname>Tian</surname><given-names>Q</given-names></name><name><surname>Dong</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Critical regulation of early Th17 cell differentiation by Interleukin-1 signaling</article-title><source>Immunity</source><volume>30</volume><fpage>576</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2009.02.007</pub-id><pub-id pub-id-type="pmid">19362022</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>KM</given-names></name><name><surname>Kim</surname><given-names>JG</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Presti</surname><given-names>RM</given-names></name><name><surname>Shan</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Chemical inhibition of Dpp9 sensitizes the Card8 Inflammasome in HIV-1-infected cells</article-title><source>Nature Chemical Biology</source><volume>19</volume><fpage>431</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1038/s41589-022-01182-5</pub-id><pub-id pub-id-type="pmid">36357533</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daugherty</surname><given-names>MD</given-names></name><name><surname>Malik</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Rules of engagement: molecular insights from host-virus arms races</article-title><source>Annual Review of Genetics</source><volume>46</volume><fpage>677</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1146/annurev-genet-110711-155522</pub-id><pub-id pub-id-type="pmid">23145935</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doitsh</surname><given-names>G</given-names></name><name><surname>Galloway</surname><given-names>NLK</given-names></name><name><surname>Geng</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Monroe</surname><given-names>KM</given-names></name><name><surname>Zepeda</surname><given-names>O</given-names></name><name><surname>Hunt</surname><given-names>PW</given-names></name><name><surname>Hatano</surname><given-names>H</given-names></name><name><surname>Sowinski</surname><given-names>S</given-names></name><name><surname>MuÃ±oz-Arias</surname><given-names>I</given-names></name><name><surname>Greene</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Pyroptosis drives Cd4 T-cell depletion in HIV-1 infection</article-title><source>Nature</source><volume>505</volume><fpage>509</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1038/nature12940</pub-id><pub-id pub-id-type="pmid">24356306</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DâOsualdo</surname><given-names>A</given-names></name><name><surname>Weichenberger</surname><given-names>CX</given-names></name><name><surname>Wagner</surname><given-names>RN</given-names></name><name><surname>Godzik</surname><given-names>A</given-names></name><name><surname>Wooley</surname><given-names>J</given-names></name><name><surname>Reed</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Card8 and Nlrp1 undergo Autoproteolytic processing through a Zu5-like domain</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e27396</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0027396</pub-id><pub-id pub-id-type="pmid">22087307</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Etienne</surname><given-names>L</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name><name><surname>Sharp</surname><given-names>PM</given-names></name><name><surname>Matsen</surname><given-names>FA</given-names></name><name><surname>Emerman</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Gene loss and adaptation to Hominids underlie the ancient origin of HIV-1</article-title><source>Cell Host &amp; Microbe</source><volume>14</volume><fpage>85</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2013.06.002</pub-id><pub-id pub-id-type="pmid">23870316</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figueiredo</surname><given-names>A</given-names></name><name><surname>Moore</surname><given-names>KL</given-names></name><name><surname>Mak</surname><given-names>J</given-names></name><name><surname>Sluis-Cremer</surname><given-names>N</given-names></name><name><surname>de Bethune</surname><given-names>MP</given-names></name><name><surname>Tachedjian</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Potent Nonnucleoside reverse transcriptase inhibitors target HIV-1 gag-Pol</article-title><source>PLOS Pathogens</source><volume>2</volume><elocation-id>e119</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.0020119</pub-id><pub-id pub-id-type="pmid">17096588</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fink</surname><given-names>SL</given-names></name><name><surname>Cookson</surname><given-names>BT</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Apoptosis, Pyroptosis, and necrosis: mechanistic description of dead and dying Eukaryotic cells</article-title><source>Infection and Immunity</source><volume>73</volume><fpage>1907</fpage><lpage>1916</lpage><pub-id pub-id-type="doi">10.1128/IAI.73.4.1907-1916.2005</pub-id><pub-id pub-id-type="pmid">15784530</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>RE</given-names></name><name><surname>Krause</surname><given-names>J</given-names></name><name><surname>Briggs</surname><given-names>AW</given-names></name><name><surname>Maricic</surname><given-names>T</given-names></name><name><surname>Stenzel</surname><given-names>U</given-names></name><name><surname>Kircher</surname><given-names>M</given-names></name><name><surname>Patterson</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zhai</surname><given-names>W</given-names></name><name><surname>Fritz</surname><given-names>MHY</given-names></name><name><surname>Hansen</surname><given-names>NF</given-names></name><name><surname>Durand</surname><given-names>EY</given-names></name><name><surname>Malaspinas</surname><given-names>AS</given-names></name><name><surname>Jensen</surname><given-names>JD</given-names></name><name><surname>Marques-Bonet</surname><given-names>T</given-names></name><name><surname>Alkan</surname><given-names>C</given-names></name><name><surname>PrÃ¼fer</surname><given-names>K</given-names></name><name><surname>Meyer</surname><given-names>M</given-names></name><name><surname>Burbano</surname><given-names>HA</given-names></name><name><surname>Good</surname><given-names>JM</given-names></name><name><surname>Schultz</surname><given-names>R</given-names></name><name><surname>Aximu-Petri</surname><given-names>A</given-names></name><name><surname>Butthof</surname><given-names>A</given-names></name><name><surname>HÃ¶ber</surname><given-names>B</given-names></name><name><surname>HÃ¶ffner</surname><given-names>B</given-names></name><name><surname>Siegemund</surname><given-names>M</given-names></name><name><surname>Weihmann</surname><given-names>A</given-names></name><name><surname>Nusbaum</surname><given-names>C</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Russ</surname><given-names>C</given-names></name><name><surname>Novod</surname><given-names>N</given-names></name><name><surname>Affourtit</surname><given-names>J</given-names></name><name><surname>Egholm</surname><given-names>M</given-names></name><name><surname>Verna</surname><given-names>C</given-names></name><name><surname>Rudan</surname><given-names>P</given-names></name><name><surname>Brajkovic</surname><given-names>D</given-names></name><name><surname>Kucan</surname><given-names>Å½</given-names></name><name><surname>GuÅ¡ic</surname><given-names>I</given-names></name><name><surname>Doronichev</surname><given-names>VB</given-names></name><name><surname>Golovanova</surname><given-names>LV</given-names></name><name><surname>Lalueza-Fox</surname><given-names>C</given-names></name><name><surname>de la Rasilla</surname><given-names>M</given-names></name><name><surname>Fortea</surname><given-names>J</given-names></name><name><surname>Rosas</surname><given-names>A</given-names></name><name><surname>Schmitz</surname><given-names>RW</given-names></name><name><surname>Johnson</surname><given-names>PLF</given-names></name><name><surname>Eichler</surname><given-names>EE</given-names></name><name><surname>Falush</surname><given-names>D</given-names></name><name><surname>Birney</surname><given-names>E</given-names></name><name><surname>Mullikin</surname><given-names>JC</given-names></name><name><surname>Slatkin</surname><given-names>M</given-names></name><name><surname>Nielsen</surname><given-names>R</given-names></name><name><surname>Kelso</surname><given-names>J</given-names></name><name><surname>Lachmann</surname><given-names>M</given-names></name><name><surname>Reich</surname><given-names>D</given-names></name><name><surname>PÃ¤Ã¤bo</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A draft sequence of the Neandertal genome</article-title><source>Science</source><volume>328</volume><fpage>710</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1126/science.1188021</pub-id><pub-id pub-id-type="pmid">20448178</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gummuluru</surname><given-names>S</given-names></name><name><surname>Rogel</surname><given-names>M</given-names></name><name><surname>Stamatatos</surname><given-names>L</given-names></name><name><surname>Emerman</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Binding of human immunodeficiency virus type 1 to immature Dendritic cells can occur independently of DC-SIGN and mannose binding C-type lectin receptors via a cholesterol-dependent pathway</article-title><source>Journal of Virology</source><volume>77</volume><fpage>12865</fpage><lpage>12874</lpage><pub-id pub-id-type="doi">10.1128/jvi.77.23.12865-12874.2003</pub-id><pub-id pub-id-type="pmid">14610207</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guyader</surname><given-names>M</given-names></name><name><surname>Emerman</surname><given-names>M</given-names></name><name><surname>Sonigo</surname><given-names>P</given-names></name><name><surname>Clavel</surname><given-names>F</given-names></name><name><surname>Montagnier</surname><given-names>L</given-names></name><name><surname>Alizon</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Genome organization and Transactivation of the human immunodeficiency virus type 2</article-title><source>Nature</source><volume>326</volume><fpage>662</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1038/326662a0</pub-id><pub-id pub-id-type="pmid">3031510</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haddox</surname><given-names>HK</given-names></name><name><surname>Dingens</surname><given-names>AS</given-names></name><name><surname>Hilton</surname><given-names>SK</given-names></name><name><surname>Overbaugh</surname><given-names>J</given-names></name><name><surname>Bloom</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mapping mutational effects along the evolutionary landscape of HIV envelope</article-title><source>eLife</source><volume>7</volume><elocation-id>e34420</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.34420</pub-id><pub-id pub-id-type="pmid">29590010</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsiao</surname><given-names>JC</given-names></name><name><surname>Neugroschl</surname><given-names>AR</given-names></name><name><surname>Chui</surname><given-names>AJ</given-names></name><name><surname>Taabazuing</surname><given-names>CY</given-names></name><name><surname>Griswold</surname><given-names>AR</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>HC</given-names></name><name><surname>Orth-He</surname><given-names>EL</given-names></name><name><surname>Ball</surname><given-names>DP</given-names></name><name><surname>Hiotis</surname><given-names>G</given-names></name><name><surname>Bachovchin</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A Ubiquitin-independent Proteasome pathway controls activation of the Card8 Inflammasome</article-title><source>The Journal of Biological Chemistry</source><volume>298</volume><elocation-id>102032</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2022.102032</pub-id><pub-id pub-id-type="pmid">35580636</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jasinska</surname><given-names>AJ</given-names></name><name><surname>Apetrei</surname><given-names>C</given-names></name><name><surname>Pandrea</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Walk on the wild side: SIV infection in African non-human Primate hosts-from the field to the laboratory</article-title><source>Frontiers in Immunology</source><volume>13</volume><elocation-id>1060985</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.1060985</pub-id><pub-id pub-id-type="pmid">36713371</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>D C</given-names></name><name><surname>Taabazuing</surname><given-names>CY</given-names></name><name><surname>Okondo</surname><given-names>MC</given-names></name><name><surname>Chui</surname><given-names>AJ</given-names></name><name><surname>Rao</surname><given-names>SD</given-names></name><name><surname>Brown</surname><given-names>FC</given-names></name><name><surname>Reed</surname><given-names>C</given-names></name><name><surname>Peguero</surname><given-names>E</given-names></name><name><surname>de Stanchina</surname><given-names>E</given-names></name><name><surname>Kentsis</surname><given-names>A</given-names></name><name><surname>Bachovchin</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Dpp8/9 inhibitor-induced Pyroptosis for treatment of acute myeloid leukemia</article-title><source>Nature Medicine</source><volume>24</volume><fpage>1151</fpage><lpage>1156</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0082-y</pub-id><pub-id pub-id-type="pmid">29967349</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>D.C</given-names></name><name><surname>Okondo</surname><given-names>MC</given-names></name><name><surname>Orth</surname><given-names>EL</given-names></name><name><surname>Rao</surname><given-names>SD</given-names></name><name><surname>Huang</surname><given-names>HC</given-names></name><name><surname>Ball</surname><given-names>DP</given-names></name><name><surname>Bachovchin</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Dpp8/9 inhibitors activate the Card8 Inflammasome in resting lymphocytes</article-title><source>Cell Death &amp; Disease</source><volume>11</volume><elocation-id>628</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-020-02865-4</pub-id><pub-id pub-id-type="pmid">32796818</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>A</given-names></name><name><surname>Grant</surname><given-names>RM</given-names></name><name><surname>Means</surname><given-names>RE</given-names></name><name><surname>McClure</surname><given-names>H</given-names></name><name><surname>Feinberg</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>RP</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Diverse host responses and outcomes following Simian immunodeficiency virus Sivmac239 infection in sooty Mangabeys and Rhesus macaques</article-title><source>Journal of Virology</source><volume>72</volume><fpage>9597</fpage><lpage>9611</lpage><pub-id pub-id-type="doi">10.1128/JVI.72.12.9597-9611.1998</pub-id><pub-id pub-id-type="pmid">9811693</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keele</surname><given-names>BF</given-names></name><name><surname>Van Heuverswyn</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Bailes</surname><given-names>E</given-names></name><name><surname>Takehisa</surname><given-names>J</given-names></name><name><surname>Santiago</surname><given-names>ML</given-names></name><name><surname>Bibollet-Ruche</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wain</surname><given-names>LV</given-names></name><name><surname>Liegeois</surname><given-names>F</given-names></name><name><surname>Loul</surname><given-names>S</given-names></name><name><surname>Ngole</surname><given-names>EM</given-names></name><name><surname>Bienvenue</surname><given-names>Y</given-names></name><name><surname>Delaporte</surname><given-names>E</given-names></name><name><surname>Brookfield</surname><given-names>JFY</given-names></name><name><surname>Sharp</surname><given-names>PM</given-names></name><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>Peeters</surname><given-names>M</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Chimpanzee reservoirs of pandemic and Nonpandemic HIV-1</article-title><source>Science</source><volume>313</volume><fpage>523</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1126/science.1126531</pub-id><pub-id pub-id-type="pmid">16728595</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keele</surname><given-names>BF</given-names></name><name><surname>Jones</surname><given-names>JH</given-names></name><name><surname>Terio</surname><given-names>KA</given-names></name><name><surname>Estes</surname><given-names>JD</given-names></name><name><surname>Rudicell</surname><given-names>RS</given-names></name><name><surname>Wilson</surname><given-names>ML</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Learn</surname><given-names>GH</given-names></name><name><surname>Beasley</surname><given-names>TM</given-names></name><name><surname>Schumacher-Stankey</surname><given-names>J</given-names></name><name><surname>Wroblewski</surname><given-names>E</given-names></name><name><surname>Mosser</surname><given-names>A</given-names></name><name><surname>Raphael</surname><given-names>J</given-names></name><name><surname>Kamenya</surname><given-names>S</given-names></name><name><surname>Lonsdorf</surname><given-names>EV</given-names></name><name><surname>Travis</surname><given-names>DA</given-names></name><name><surname>Mlengeya</surname><given-names>T</given-names></name><name><surname>Kinsel</surname><given-names>MJ</given-names></name><name><surname>Else</surname><given-names>JG</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name><name><surname>Goodall</surname><given-names>J</given-names></name><name><surname>Sharp</surname><given-names>PM</given-names></name><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>Pusey</surname><given-names>AE</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Increased mortality and AIDS-like Immunopathology in wild chimpanzees infected with Sivcpz</article-title><source>Nature</source><volume>460</volume><fpage>515</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1038/nature08200</pub-id><pub-id pub-id-type="pmid">19626114</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JG</given-names></name><name><surname>Shan</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Beyond inhibition: A novel strategy of targeting HIV-1 protease to eliminate viral reservoirs</article-title><source>Viruses</source><volume>14</volume><elocation-id>1179</elocation-id><pub-id pub-id-type="doi">10.3390/v14061179</pub-id><pub-id pub-id-type="pmid">35746649</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labun</surname><given-names>K</given-names></name><name><surname>Montague</surname><given-names>TG</given-names></name><name><surname>Krause</surname><given-names>M</given-names></name><name><surname>Torres Cleuren</surname><given-names>YN</given-names></name><name><surname>Tjeldnes</surname><given-names>H</given-names></name><name><surname>Valen</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CHOPCHOP V3: expanding the CRISPR web Toolbox beyond genome editing</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>W171</fpage><lpage>W174</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz365</pub-id><pub-id pub-id-type="pmid">31106371</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>ES</given-names></name><name><surname>Malik</surname><given-names>HS</given-names></name><name><surname>Emerman</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Ancient adaptive evolution of Tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and Primate Lentiviruses</article-title><source>Journal of Virology</source><volume>84</volume><fpage>7124</fpage><lpage>7134</lpage><pub-id pub-id-type="doi">10.1128/JVI.00468-10</pub-id><pub-id pub-id-type="pmid">20444900</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linder</surname><given-names>A</given-names></name><name><surname>Bauernfried</surname><given-names>S</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Albanese</surname><given-names>M</given-names></name><name><surname>Jung</surname><given-names>C</given-names></name><name><surname>Keppler</surname><given-names>OT</given-names></name><name><surname>Hornung</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Card8 Inflammasome activation triggers Pyroptosis in human T cells</article-title><source>The EMBO Journal</source><volume>39</volume><elocation-id>e105071</elocation-id><pub-id pub-id-type="doi">10.15252/embj.2020105071</pub-id><pub-id pub-id-type="pmid">32840892</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammadi</surname><given-names>P</given-names></name><name><surname>Desfarges</surname><given-names>S</given-names></name><name><surname>Bartha</surname><given-names>I</given-names></name><name><surname>Joos</surname><given-names>B</given-names></name><name><surname>Zangger</surname><given-names>N</given-names></name><name><surname>MuÃ±oz</surname><given-names>M</given-names></name><name><surname>GÃ¼nthard</surname><given-names>HF</given-names></name><name><surname>Beerenwinkel</surname><given-names>N</given-names></name><name><surname>Telenti</surname><given-names>A</given-names></name><name><surname>Ciuffi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>24 hours in the life of HIV-1 in a T cell line</article-title><source>PLOS Pathogens</source><volume>9</volume><elocation-id>e1003161</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003161</pub-id><pub-id pub-id-type="pmid">23382686</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monroe</surname><given-names>KM</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Johnson</surname><given-names>JR</given-names></name><name><surname>Geng</surname><given-names>X</given-names></name><name><surname>Doitsh</surname><given-names>G</given-names></name><name><surname>Krogan</surname><given-names>NJ</given-names></name><name><surname>Greene</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Ifi16 DNA sensor is required for death of Lymphoid Cd4 T-cells Abortively infected with HIV</article-title><source>Science</source><volume>343</volume><fpage>428</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1126/science.1243640</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montoya</surname><given-names>VR</given-names></name><name><surname>Ready</surname><given-names>TM</given-names></name><name><surname>Felton</surname><given-names>A</given-names></name><name><surname>Fine</surname><given-names>SR</given-names></name><name><surname>OhAinle</surname><given-names>M</given-names></name><name><surname>Emerman</surname><given-names>M</given-names></name><name><surname>Engelman</surname><given-names>AN</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>A virus-Packageable CRISPR system identifies host dependency factors Co-opted by multiple HIV-1 strains</article-title><source>mBio</source><volume>14</volume><elocation-id>e0000923</elocation-id><pub-id pub-id-type="doi">10.1128/mbio.00009-23</pub-id><pub-id pub-id-type="pmid">36744886</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>KP</given-names></name><name><surname>Schwaid</surname><given-names>AG</given-names></name><name><surname>Tudor</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Beshore</surname><given-names>DC</given-names></name><name><surname>Converso</surname><given-names>A</given-names></name><name><surname>Shipe</surname><given-names>WD</given-names></name><name><surname>Anand</surname><given-names>R</given-names></name><name><surname>Lan</surname><given-names>P</given-names></name><name><surname>Moningka</surname><given-names>R</given-names></name><name><surname>Rothman</surname><given-names>DM</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Chi</surname><given-names>A</given-names></name><name><surname>Cornella-Taracido</surname><given-names>I</given-names></name><name><surname>Adam</surname><given-names>GC</given-names></name><name><surname>Bahnck-Teets</surname><given-names>C</given-names></name><name><surname>Carroll</surname><given-names>SS</given-names></name><name><surname>Fay</surname><given-names>JF</given-names></name><name><surname>Goh</surname><given-names>SL</given-names></name><name><surname>Lusen</surname><given-names>J</given-names></name><name><surname>Quan</surname><given-names>S</given-names></name><name><surname>Rodriguez</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Andrews</surname><given-names>CL</given-names></name><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Filzen</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Hollenstein</surname><given-names>K</given-names></name><name><surname>Klein</surname><given-names>DJ</given-names></name><name><surname>Lammens</surname><given-names>A</given-names></name><name><surname>Lim</surname><given-names>UM</given-names></name><name><surname>Fang</surname><given-names>Z</given-names></name><name><surname>McHale</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Diamond</surname><given-names>TL</given-names></name><name><surname>Howell</surname><given-names>BJ</given-names></name><name><surname>Zuck</surname><given-names>P</given-names></name><name><surname>Balibar</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A Phenotypic screen identifies potent Dpp9 inhibitors capable of killing HIV-1 infected cells</article-title><source>ACS Chemical Biology</source><volume>17</volume><fpage>2595</fpage><lpage>2604</lpage><pub-id pub-id-type="doi">10.1021/acschembio.2c00515</pub-id><pub-id pub-id-type="pmid">36044633</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muema</surname><given-names>DM</given-names></name><name><surname>Akilimali</surname><given-names>NA</given-names></name><name><surname>Ndumnego</surname><given-names>OC</given-names></name><name><surname>Rasehlo</surname><given-names>SS</given-names></name><name><surname>Durgiah</surname><given-names>R</given-names></name><name><surname>Ojwach</surname><given-names>DBA</given-names></name><name><surname>Ismail</surname><given-names>N</given-names></name><name><surname>Dong</surname><given-names>M</given-names></name><name><surname>Moodley</surname><given-names>A</given-names></name><name><surname>Dong</surname><given-names>KL</given-names></name><name><surname>Ndhlovu</surname><given-names>ZM</given-names></name><name><surname>Mabuka</surname><given-names>JM</given-names></name><name><surname>Walker</surname><given-names>BD</given-names></name><name><surname>Mann</surname><given-names>JK</given-names></name><name><surname>Ndungâu</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Association between the cytokine storm, immune cell Dynamics, and viral Replicative capacity in Hyperacute HIV infection</article-title><source>BMC Medicine</source><volume>18</volume><elocation-id>81</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-020-01529-6</pub-id><pub-id pub-id-type="pmid">32209092</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MuÃ±oz-Arias</surname><given-names>I</given-names></name><name><surname>Doitsh</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Sowinski</surname><given-names>S</given-names></name><name><surname>Ruelas</surname><given-names>D</given-names></name><name><surname>Greene</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Blood-derived Cd4 T cells naturally resist Pyroptosis during abortive HIV-1 infection</article-title><source>Cell Host &amp; Microbe</source><volume>18</volume><fpage>463</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2015.09.010</pub-id><pub-id pub-id-type="pmid">26468749</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nadkarni</surname><given-names>R</given-names></name><name><surname>Chu</surname><given-names>WC</given-names></name><name><surname>Lee</surname><given-names>CQE</given-names></name><name><surname>Mohamud</surname><given-names>Y</given-names></name><name><surname>Yap</surname><given-names>L</given-names></name><name><surname>Toh</surname><given-names>GA</given-names></name><name><surname>Beh</surname><given-names>S</given-names></name><name><surname>Lim</surname><given-names>R</given-names></name><name><surname>Fan</surname><given-names>YM</given-names></name><name><surname>Zhang</surname><given-names>YL</given-names></name><name><surname>Robinson</surname><given-names>K</given-names></name><name><surname>Tryggvason</surname><given-names>K</given-names></name><name><surname>Luo</surname><given-names>H</given-names></name><name><surname>Zhong</surname><given-names>F</given-names></name><name><surname>Ho</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Viral proteases activate the Card8 Inflammasome in the human cardiovascular system</article-title><source>The Journal of Experimental Medicine</source><volume>219</volume><elocation-id>e20212117</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20212117</pub-id><pub-id pub-id-type="pmid">36129453</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>OhAinle</surname><given-names>M</given-names></name><name><surname>Helms</surname><given-names>L</given-names></name><name><surname>Vermeire</surname><given-names>J</given-names></name><name><surname>Roesch</surname><given-names>F</given-names></name><name><surname>Humes</surname><given-names>D</given-names></name><name><surname>Basom</surname><given-names>R</given-names></name><name><surname>Delrow</surname><given-names>JJ</given-names></name><name><surname>Overbaugh</surname><given-names>J</given-names></name><name><surname>Emerman</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A virus-Packageable CRISPR screen identifies host factors mediating interferon inhibition of HIV</article-title><source>eLife</source><volume>7</volume><elocation-id>e39823</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.39823</pub-id><pub-id pub-id-type="pmid">30520725</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paiardini</surname><given-names>M</given-names></name><name><surname>MÃ¼ller-Trutwin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>HIV-associated chronic immune activation</article-title><source>Immunological Reviews</source><volume>254</volume><fpage>78</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1111/imr.12079</pub-id><pub-id pub-id-type="pmid">23772616</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parrish</surname><given-names>CR</given-names></name><name><surname>Holmes</surname><given-names>EC</given-names></name><name><surname>Morens</surname><given-names>DM</given-names></name><name><surname>Park</surname><given-names>EC</given-names></name><name><surname>Burke</surname><given-names>DS</given-names></name><name><surname>Calisher</surname><given-names>CH</given-names></name><name><surname>Laughlin</surname><given-names>CA</given-names></name><name><surname>Saif</surname><given-names>LJ</given-names></name><name><surname>Daszak</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Cross-species virus transmission and the emergence of new epidemic diseases</article-title><source>Microbiology and Molecular Biology Reviews</source><volume>72</volume><fpage>457</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1128/MMBR.00004-08</pub-id><pub-id pub-id-type="pmid">18772285</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peden</surname><given-names>K</given-names></name><name><surname>Emerman</surname><given-names>M</given-names></name><name><surname>Montagnier</surname><given-names>L</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1Lai, HIV-1Mal, and HIV-1Eli</article-title><source>Virology</source><volume>185</volume><fpage>661</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1016/0042-6822(91)90537-l</pub-id><pub-id pub-id-type="pmid">1683726</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>PlanÃ¨s</surname><given-names>R</given-names></name><name><surname>Pinilla</surname><given-names>M</given-names></name><name><surname>Santoni</surname><given-names>K</given-names></name><name><surname>Hessel</surname><given-names>A</given-names></name><name><surname>Passemar</surname><given-names>C</given-names></name><name><surname>Lay</surname><given-names>K</given-names></name><name><surname>Paillette</surname><given-names>P</given-names></name><name><surname>ValadÃ£o</surname><given-names>ALC</given-names></name><name><surname>Robinson</surname><given-names>KS</given-names></name><name><surname>Bastard</surname><given-names>P</given-names></name><name><surname>Lam</surname><given-names>N</given-names></name><name><surname>Fadrique</surname><given-names>R</given-names></name><name><surname>Rossi</surname><given-names>I</given-names></name><name><surname>Pericat</surname><given-names>D</given-names></name><name><surname>Bagayoko</surname><given-names>S</given-names></name><name><surname>Leon-Icaza</surname><given-names>SA</given-names></name><name><surname>Rombouts</surname><given-names>Y</given-names></name><name><surname>Perouzel</surname><given-names>E</given-names></name><name><surname>Tiraby</surname><given-names>M</given-names></name><collab>COVID Human Genetic Effort</collab><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Cicuta</surname><given-names>P</given-names></name><name><surname>Jouanguy</surname><given-names>E</given-names></name><name><surname>Neyrolles</surname><given-names>O</given-names></name><name><surname>Bryant</surname><given-names>CE</given-names></name><name><surname>Floto</surname><given-names>AR</given-names></name><name><surname>Goujon</surname><given-names>C</given-names></name><name><surname>Lei</surname><given-names>FZ</given-names></name><name><surname>Martin-Blondel</surname><given-names>G</given-names></name><name><surname>Silva</surname><given-names>S</given-names></name><name><surname>Casanova</surname><given-names>JL</given-names></name><name><surname>Cougoule</surname><given-names>C</given-names></name><name><surname>Reversade</surname><given-names>B</given-names></name><name><surname>Marcoux</surname><given-names>J</given-names></name><name><surname>Ravet</surname><given-names>E</given-names></name><name><surname>Meunier</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung epithelial cells</article-title><source>Molecular Cell</source><volume>82</volume><fpage>2385</fpage><lpage>2400</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2022.04.033</pub-id><pub-id pub-id-type="pmid">35594856</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poss</surname><given-names>M</given-names></name><name><surname>Overbaugh</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties</article-title><source>Journal of Virology</source><volume>73</volume><fpage>5255</fpage><lpage>5264</lpage><pub-id pub-id-type="doi">10.1128/JVI.73.7.5255-5264.1999</pub-id><pub-id pub-id-type="pmid">10364271</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>SD</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Orth-He</surname><given-names>EL</given-names></name><name><surname>Saoi</surname><given-names>M</given-names></name><name><surname>Griswold</surname><given-names>AR</given-names></name><name><surname>Bhattacharjee</surname><given-names>A</given-names></name><name><surname>Ball</surname><given-names>DP</given-names></name><name><surname>Huang</surname><given-names>H-C</given-names></name><name><surname>Chui</surname><given-names>AJ</given-names></name><name><surname>Covelli</surname><given-names>DJ</given-names></name><name><surname>You</surname><given-names>S</given-names></name><name><surname>Cross</surname><given-names>JR</given-names></name><name><surname>Bachovchin</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>M24B Aminopeptidase inhibitors selectively activate the Card8 Inflammasome</article-title><source>Nature Chemical Biology</source><volume>18</volume><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1038/s41589-021-00964-7</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rider</surname><given-names>P</given-names></name><name><surname>Carmi</surname><given-names>Y</given-names></name><name><surname>Guttman</surname><given-names>O</given-names></name><name><surname>Braiman</surname><given-names>A</given-names></name><name><surname>Cohen</surname><given-names>I</given-names></name><name><surname>Voronov</surname><given-names>E</given-names></name><name><surname>White</surname><given-names>MR</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Apte</surname><given-names>RN</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>IL-1Î and IL-1Î recruit different myeloid cells and promote different stages of sterile inflammation</article-title><source>Journal of Immunology</source><volume>187</volume><fpage>4835</fpage><lpage>4843</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1102048</pub-id><pub-id pub-id-type="pmid">21930960</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>KS</given-names></name><name><surname>Teo</surname><given-names>DET</given-names></name><name><surname>Tan</surname><given-names>KS</given-names></name><name><surname>Toh</surname><given-names>GA</given-names></name><name><surname>Ong</surname><given-names>HH</given-names></name><name><surname>Lim</surname><given-names>CK</given-names></name><name><surname>Lay</surname><given-names>K</given-names></name><name><surname>Au</surname><given-names>BV</given-names></name><name><surname>Lew</surname><given-names>TS</given-names></name><name><surname>Chu</surname><given-names>JJH</given-names></name><name><surname>Chow</surname><given-names>VTK</given-names></name><name><surname>Wang</surname><given-names>DY</given-names></name><name><surname>Zhong</surname><given-names>FL</given-names></name><name><surname>Reversade</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Enteroviral 3C protease activates the human Nlrp1 Inflammasome in airway Epithelia</article-title><source>Science</source><volume>370</volume><elocation-id>eaay2002</elocation-id><pub-id pub-id-type="doi">10.1126/science.aay2002</pub-id><pub-id pub-id-type="pmid">33093214</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogel</surname><given-names>ME</given-names></name><name><surname>Wu</surname><given-names>LI</given-names></name><name><surname>Emerman</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>The human immunodeficiency virus type 1 Vpr gene prevents cell proliferation during chronic infection</article-title><source>Journal of Virology</source><volume>69</volume><fpage>882</fpage><lpage>888</lpage><pub-id pub-id-type="doi">10.1128/JVI.69.2.882-888.1995</pub-id><pub-id pub-id-type="pmid">7815556</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandler</surname><given-names>NG</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Microbial translocation in HIV infection: causes, consequences and treatment opportunities</article-title><source>Nature Reviews. Microbiology</source><volume>10</volume><fpage>655</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2848</pub-id><pub-id pub-id-type="pmid">22886237</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandstrom</surname><given-names>A</given-names></name><name><surname>Mitchell</surname><given-names>PS</given-names></name><name><surname>Goers</surname><given-names>L</given-names></name><name><surname>Mu</surname><given-names>EW</given-names></name><name><surname>Lesser</surname><given-names>CF</given-names></name><name><surname>Vance</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Functional degradation: A mechanism of Nlrp1 Inflammasome activation by diverse pathogen enzymes</article-title><source>Science</source><volume>364</volume><elocation-id>eaau1330</elocation-id><pub-id pub-id-type="doi">10.1126/science.aau1330</pub-id><pub-id pub-id-type="pmid">30872533</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauter</surname><given-names>D</given-names></name><name><surname>Schindler</surname><given-names>M</given-names></name><name><surname>Specht</surname><given-names>A</given-names></name><name><surname>Landford</surname><given-names>WN</given-names></name><name><surname>MÃ¼nch</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>KA</given-names></name><name><surname>Votteler</surname><given-names>J</given-names></name><name><surname>Schubert</surname><given-names>U</given-names></name><name><surname>Bibollet-Ruche</surname><given-names>F</given-names></name><name><surname>Keele</surname><given-names>BF</given-names></name><name><surname>Takehisa</surname><given-names>J</given-names></name><name><surname>Ogando</surname><given-names>Y</given-names></name><name><surname>Ochsenbauer</surname><given-names>C</given-names></name><name><surname>Kappes</surname><given-names>JC</given-names></name><name><surname>Ayouba</surname><given-names>A</given-names></name><name><surname>Peeters</surname><given-names>M</given-names></name><name><surname>Learn</surname><given-names>GH</given-names></name><name><surname>Shaw</surname><given-names>G</given-names></name><name><surname>Sharp</surname><given-names>PM</given-names></name><name><surname>Bieniasz</surname><given-names>P</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name><name><surname>Hatziioannou</surname><given-names>T</given-names></name><name><surname>Kirchhoff</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and Nonpandemic HIV-1 strains</article-title><source>Cell Host &amp; Microbe</source><volume>6</volume><fpage>409</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2009.10.004</pub-id><pub-id pub-id-type="pmid">19917496</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmid-Burgk</surname><given-names>JL</given-names></name><name><surname>Schmidt</surname><given-names>T</given-names></name><name><surname>Gaidt</surname><given-names>MM</given-names></name><name><surname>Pelka</surname><given-names>K</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name><name><surname>Ebert</surname><given-names>TS</given-names></name><name><surname>Hornung</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Outknocker: a web tool for rapid and simple Genotyping of designer Nuclease edited cell lines</article-title><source>Genome Research</source><volume>24</volume><fpage>1719</fpage><lpage>1723</lpage><pub-id pub-id-type="doi">10.1101/gr.176701.114</pub-id><pub-id pub-id-type="pmid">25186908</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>T</given-names></name><name><surname>Schmid-Burgk</surname><given-names>JL</given-names></name><name><surname>Ebert</surname><given-names>TS</given-names></name><name><surname>Gaidt</surname><given-names>MM</given-names></name><name><surname>Hornung</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2016">2016</year><chapter-title>Designer Nuclease-mediated generation of knockout Thp1 cells in</chapter-title><person-group person-group-type="editor"><name><surname>KÃ¼hn</surname><given-names>R</given-names></name><name><surname>Wurst</surname><given-names>W</given-names></name><name><surname>Wefers</surname><given-names>B</given-names></name></person-group><source>TALENs, Methods in Molecular Biology</source><publisher-loc>New York</publisher-loc><publisher-name>Springer</publisher-name><fpage>261</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-2932-0</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharif</surname><given-names>H</given-names></name><name><surname>Hollingsworth</surname><given-names>LR</given-names></name><name><surname>Griswold</surname><given-names>AR</given-names></name><name><surname>Hsiao</surname><given-names>JC</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Bachovchin</surname><given-names>DA</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Dipeptidyl Peptidase 9 sets a threshold for Card8 Inflammasome formation by Sequestering its active C-terminal fragment</article-title><source>Immunity</source><volume>54</volume><fpage>1392</fpage><lpage>1404</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2021.04.024</pub-id><pub-id pub-id-type="pmid">34019797</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharp</surname><given-names>PM</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The evolution of HIV-1 and the origin of AIDS</article-title><source>Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences</source><volume>365</volume><fpage>2487</fpage><lpage>2494</lpage><pub-id pub-id-type="doi">10.1098/rstb.2010.0031</pub-id><pub-id pub-id-type="pmid">20643738</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharp</surname><given-names>PM</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Origins of HIV and the AIDS pandemic</article-title><source>Cold Spring Harbor Perspectives in Medicine</source><volume>1</volume><elocation-id>a006841</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a006841</pub-id><pub-id pub-id-type="pmid">22229120</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sparrer</surname><given-names>KMJ</given-names></name><name><surname>Kirchhoff</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>HIV protease: late action to prevent immune detection</article-title><source>Signal Transduction and Targeted Therapy</source><volume>6</volume><elocation-id>157</elocation-id><pub-id pub-id-type="doi">10.1038/s41392-021-00588-2</pub-id><pub-id pub-id-type="pmid">33863875</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steiner</surname><given-names>A</given-names></name><name><surname>Harapas</surname><given-names>CR</given-names></name><name><surname>Masters</surname><given-names>SL</given-names></name><name><surname>Davidson</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>An update on Autoinflammatory diseases: Inflammasomopathies</article-title><source>Current Rheumatology Reports</source><volume>20</volume><elocation-id>39</elocation-id><pub-id pub-id-type="doi">10.1007/s11926-018-0749-x</pub-id><pub-id pub-id-type="pmid">29846841</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taabazuing</surname><given-names>CY</given-names></name><name><surname>Griswold</surname><given-names>AR</given-names></name><name><surname>Bachovchin</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The Nlrp1 and Card8 Inflammasomes</article-title><source>Immunological Reviews</source><volume>297</volume><fpage>13</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1111/imr.12884</pub-id><pub-id pub-id-type="pmid">32558991</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabler</surname><given-names>CO</given-names></name><name><surname>Wegman</surname><given-names>SJ</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Shroff</surname><given-names>H</given-names></name><name><surname>Alhusaini</surname><given-names>N</given-names></name><name><surname>Tilton</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The HIV-1 viral protease is activated during assembly and budding prior to particle release</article-title><source>Journal of Virology</source><volume>96</volume><elocation-id>e0219821</elocation-id><pub-id pub-id-type="doi">10.1128/jvi.02198-21</pub-id><pub-id pub-id-type="pmid">35438536</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>TrinitÃ©</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Levy</surname><given-names>DN</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>NNRTI-induced HIV-1 protease-mediated cytotoxicity induces rapid death of Cd4 T cells during productive infection and latency reversal</article-title><source>Retrovirology</source><volume>16</volume><elocation-id>17</elocation-id><pub-id pub-id-type="doi">10.1186/s12977-019-0479-9</pub-id><pub-id pub-id-type="pmid">31242909</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsu</surname><given-names>BV</given-names></name><name><surname>Beierschmitt</surname><given-names>C</given-names></name><name><surname>Ryan</surname><given-names>AP</given-names></name><name><surname>Agarwal</surname><given-names>R</given-names></name><name><surname>Mitchell</surname><given-names>PS</given-names></name><name><surname>Daugherty</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Diverse viral proteases activate the Nlrp1 Inflammasome</article-title><source>eLife</source><volume>10</volume><elocation-id>e60609</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.60609</pub-id><pub-id pub-id-type="pmid">33410748</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsu</surname><given-names>BV</given-names></name><name><surname>Fay</surname><given-names>EJ</given-names></name><name><surname>Nguyen</surname><given-names>KT</given-names></name><name><surname>Corley</surname><given-names>MR</given-names></name><name><surname>Hosuru</surname><given-names>B</given-names></name><name><surname>Dominguez</surname><given-names>VA</given-names></name><name><surname>Daugherty</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Running with scissors: evolutionary conflicts between viral proteases and the host immune system</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>769543</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.769543</pub-id><pub-id pub-id-type="pmid">34790204</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsu</surname><given-names>BV</given-names></name><name><surname>Agarwal</surname><given-names>R</given-names></name><name><surname>Gokhale</surname><given-names>NS</given-names></name><name><surname>Kulsuptrakul</surname><given-names>J</given-names></name><name><surname>Ryan</surname><given-names>AP</given-names></name><name><surname>Fay</surname><given-names>EJ</given-names></name><name><surname>Castro</surname><given-names>LK</given-names></name><name><surname>Beierschmitt</surname><given-names>C</given-names></name><name><surname>Yap</surname><given-names>C</given-names></name><name><surname>Turcotte</surname><given-names>EA</given-names></name><name><surname>Delgado-Rodriguez</surname><given-names>SE</given-names></name><name><surname>Vance</surname><given-names>RE</given-names></name><name><surname>Hyde</surname><given-names>JL</given-names></name><name><surname>Savan</surname><given-names>R</given-names></name><name><surname>Mitchell</surname><given-names>PS</given-names></name><name><surname>Daugherty</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Host-specific sensing of Coronaviruses and Picornaviruses by the Card8 Inflammasome</article-title><source>PLOS Biology</source><volume>21</volume><elocation-id>e3002144</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3002144</pub-id><pub-id pub-id-type="pmid">37289745</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Clark</surname><given-names>KM</given-names></name><name><surname>Mugisha</surname><given-names>CS</given-names></name><name><surname>Davis</surname><given-names>K</given-names></name><name><surname>Tang</surname><given-names>JP</given-names></name><name><surname>Harlan</surname><given-names>GH</given-names></name><name><surname>DeSelm</surname><given-names>CJ</given-names></name><name><surname>Presti</surname><given-names>RM</given-names></name><name><surname>Kutluay</surname><given-names>SB</given-names></name><name><surname>Shan</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Card8 is an Inflammasome sensor for HIV-1 protease activity</article-title><source>Science</source><volume>371</volume><elocation-id>eabe1707</elocation-id><pub-id pub-id-type="doi">10.1126/science.abe1707</pub-id><pub-id pub-id-type="pmid">33542150</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Shan</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The CARD8 Inflammasome Drives CD4 <sup>+</sup> T-Cell Depletion in HIV-1 Infection</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2023.03.18.533283</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Gu</surname><given-names>Q</given-names></name><name><surname>de Manuel Montero</surname><given-names>M</given-names></name><name><surname>Bravo</surname><given-names>IG</given-names></name><name><surname>Marques-Bonet</surname><given-names>T</given-names></name><name><surname>HÃ¤ussinger</surname><given-names>D</given-names></name><name><surname>MÃ¼nk</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Stably expressed Apobec3H forms a barrier for cross-species transmission of Simian immunodeficiency virus of chimpanzee to humans</article-title><source>PLOS Pathogens</source><volume>13</volume><elocation-id>e1006746</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006746</pub-id><pub-id pub-id-type="pmid">29267382</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Song</surname><given-names>JW</given-names></name><name><surname>Huang</surname><given-names>HH</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Deng</surname><given-names>JN</given-names></name><name><surname>Tu</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>MJ</given-names></name><name><surname>Yang</surname><given-names>CX</given-names></name><name><surname>Zhao</surname><given-names>QW</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>LF</given-names></name><name><surname>Zhang</surname><given-names>JY</given-names></name><name><surname>Xu</surname><given-names>RN</given-names></name><name><surname>Jiao</surname><given-names>YM</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Shao</surname><given-names>F</given-names></name><name><surname>SÃ©kaly</surname><given-names>RP</given-names></name><name><surname>Wang</surname><given-names>FS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Nlrp3 Inflammasome induces Cd4<sup>+</sup> T cell loss in chronically HIV-1âinfected patients</article-title><source>The Journal of Clinical Investigation</source><volume>131</volume><elocation-id>e138861</elocation-id><pub-id pub-id-type="doi">10.1172/JCI138861</pub-id><pub-id pub-id-type="pmid">33720048</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84108.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kirchhoff</surname><given-names>Frank</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032000t02</institution-id><institution>Ulm University Medical Center</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.10.04.510817" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.10.04.510817"/></front-stub><body><p>Kulsuptrakul and colleagues provide convincing evidence that the human inflammasome-forming sensor CARD8 contains a specific F-F motif that allows cleavage by the proteases of HIV-1 and emerged after separation of chimpanzees and humans. In comparison, CARD8 proteins from non-human primates contain changes in this motif and are largely resistant to proteolytic activation. These important findings suggest a potential role of CARD8 cleavage and inflammasome activation in primate lentiviral pathogenesis.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84108.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kirchhoff</surname><given-names>Frank</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032000t02</institution-id><institution>Ulm University Medical Center</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Kirchhoff</surname><given-names>Frank</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032000t02</institution-id><institution>Ulm University Medical Center</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.10.04.510817">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.10.04.510817v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;A human-specific motif facilitates CARD8 inflammasome activation after HIV-1 infection&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by Frank Kirchhoff as Reviewing Editor and Reviewer #1, and Miles Davenport as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) The potential relevance for pathogenesis remains speculative since effects in primed THP-1 cells infected by VSV-G pseudotyped viruses were modest and no evidence is presented that wild-type SIVcpz or HIV-1 induces inflammatory responses in primary viral target cells in a CARD8-dependent manner. Such evidence would significantly increase the significance of the study and seems critical to warrant conclusions about the potential impact on viral pathogenesis. It should also be clearly mentioned that SIVcpz causes disease in wild chimpanzees (Keele et al., 2009).</p><p>2) Conclusions that CARD8 cleavage and inflammasome activation are human-specific should be cautioned or strengthened by further evidence that the simian CARD8 cannot be activated by SIV in relevant target cell types. While the results show that human CARD8 is more sensitive to cleavage by HIV-1 and SIVcpz protease than CPZ CARD8, the possibility that some SIV proteases may cleave CARD8 in their simian hosts cannot be excluded.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>The study is interesting and the data convincingly show that F60 renders human CARD8 sensitive to cleavage by SIVcpz and HIV-1 proteases and is associated with higher levels of cell death and IL1-Ã production in THP-1 cells infected with VSV-G pseudotyped HIV-1. The potential relevance for pathogenesis remains speculative since no evidence is presented that wild-type SIVcpz or HIV-1 induces inflammatory responses in primary viral target cells in a CARD8-dependent manner.</p><p>Specific points:</p><p>Lines 2-3. &quot;Simian immunodeficiency viruses (SIVs) are generally non-pathogenic in their natural hosts&quot;. This seems like an overstatement. It has been clearly shown that SIVcpz causes disease in wild chimpanzees (Keele et al., 2009). Also, experimental evidence for lack of disease in natural SIV infection comes mainly just from two of ~40 infected species and rare cases of the disease have even been reported in African green monkeys and sooty mangabeys.</p><p>Figure 2B: the levels of EK505 Gag-Pol proteins are pretty low. Is this due to inefficient expression or antibody recognition?</p><p>Figure 3: the levels of cell death and IL-1Ã secretion are substantially higher for VSV-G-pseudotyped HIV-1 LAI. Do the authors feel that this is just due to higher infection rates or that e.g. different sites of fusion may also contribute to the sensing effect? Do they have an explanation for why the effects of LAI on IL-Ã are not dose-dependent (panel B) and why Gag processing seems more effective for wild-type compared to VSV-G-mediated infection in panel C.</p><p>In Figures 4E and F, only VSV-G data are shown. Would increase significance if effects can be verified with wild-type HIV-1.</p><p>Pg 12, line 27: &quot;relative to HIV-infected patients who quickly progress to AIDS without treatment&quot;. Suggest to caution, an average of about 6-8 years doesn't really seem &quot;quick&quot; and is much slower than e.g. progression to simian AIDS in macaques.</p><p>Conclusions about the importance of CARD8-dependent inflammasome activation for the pathogenesis should be cautioned throughout or (better) substantiated by further experimental data.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>The authors show a protein alignment in Figure 1A. They need to specify where these data came from or what the species-specific variation is at those positions. The authors claim that only humans have phenylalanine at the 60th position. A more full phylogenetic analysis is needed to support this claim. Additionally, the aggregation of all old-world monkey species needs to be expanded upon in regard to which species are included in this analysis.</p><p>In Figure 1B, the 88/89 position was not mentioned as a protease cleavage site in previous studies. Do the authors have any experimental evidence? Otherwise, this should be removed.</p><p>Figure 1C: The band present at the 40-45kDa position is explained by the authors as being due to proteasomal degradation but should be validated through the use of proteasome inhibitors or through identifying the exact cleavage site that produces this band.</p><p>Figure 1D: There are two bands present at the predicted HIV-PR site which the lower one is present in F60S. Is this band an HIV protease cleavage site as it is present in the HIV-transfected conditions? Does this cleavage lead to functional activation of the CARD8 inflammasome? There is clear evidence of cleavage in the F60L mutant condition, while the authors state that this makes cleavage less efficient. The text should reflect that F60 is not the only amino acid that can be cleaved and should downplay the human specificity due to this cleavage still being present, albeit less efficient. There is also an increased 40-45 kda band size in the mutant conditions, does this increase correspond to alternate cleavage site use, and does the alternative cleavage lead to CARD8 activation?</p><p>Figure 2A: There is an additional band at 50kDA present in this blot that was not present in previous blots, the authors should repeat these experiments. There are also faint bands at the SIV/HIV pr cleavage site annotated. The results can be improved by doing biochemical in vitro cleavage experiments using purified CARD8 and viral particles or PR to remove any background that may affect their results.</p><p>Figure 3A: These experiments were conducted 24 hours post-infection which can allow for the production of viral proteins. The authors should use earlier time points (&lt;12hrs) or block viral RT or integration to show cell death exclusively caused by the incoming viral proteins as stated in the results. Notably, cell death was observed also in CARD8-KO cells in Figure 4C.</p><p>In figure 3B, the authors mention that priming is required for IL-1B release but not cell death. Is it just for THP-1 cells, also correct in primary macrophages?</p><p>Can the authors perform similar experiments in Figure 3 using primary CD4 T cells?</p><p>In Figures4e and f, the authors also should test whether SIVcpz activates the CARD8cpz, which may have other potential cleavage sites. They should also create other non-human primate species CARD8 proteins to show that this is a human-specific activation as their results can only draw conclusions about human variation at the cleavage site and chimpanzee CARD8 activation.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>1) The conclusion of &quot;â¦the CARD8 inflammasome as a potential driver of HIV pathogenesis&quot; is partially supported. As described in the summary above, HIV/SIVcpz PR-mediated CARD8 proteolysis at the N-terminus is inefficient to start with (Figures 1 and 2). In primed THP-1 cells, inflammasome activation associated with HIV-1 infection was detectable but much less profound compared to the VbP control.</p><p>2) Cell death measured by propidium iodide staining could be caused by multifold factors and thus is a rather generic pathological marker. HIV infection also has a pathological impact independent of PR activity, which is difficult to distinguish with the reported experimental approaches. Accordingly, these factors should be taken into consideration for the interpretation of cell death data.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84108.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The potential relevance for pathogenesis remains speculative since effects in primed THP-1 cells infected by VSV-G pseudotyped viruses were modest and no evidence is presented that wild-type SIVcpz or HIV-1 induces inflammatory responses in primary viral target cells in a CARD8-dependent manner. Such evidence would significantly increase the significance of the study and seems critical to warrant conclusions about the potential impact on viral pathogenesis. It should also be clearly mentioned that SIVcpz causes disease in wild chimpanzees (Keele et al., 2009).</p></disp-quote><p>Yes, we agree that the relevance for pathogenesis is speculative. We have extensively rewritten the manuscript to focus on the evolutionary and mechanistic aspects of lentiviral protease-dependent activation of the CARD8 inflammasome that this manuscript provides. We have moved all of the pathogenesis speculation, including clearly stating that SIVcpz causes disease in wild chimpanzees, to the Discussion where it is clearly marked as speculation.</p><p>We also point out that other groups have now independently shown that HIV-1 protease induces CARD8 inflammasome activation in primary T cells (Wang et al., 2021, Science; Clark et al. 2022, Nature Chem Biol; Balibar et al. 2023, Science Trans Med; Wang and Shan, 2023, BioRxiv). We now cite these references to contextualize our Discussion.</p><disp-quote content-type="editor-comment"><p>2) Conclusions that CARD8 cleavage and inflammasome activation are human-specific should be cautioned or strengthened by further evidence that the simian CARD8 cannot be activated by SIV in relevant target cell types. While the results show that human CARD8 is more sensitive to cleavage by HIV-1 and SIVcpz protease than CPZ CARD8, the possibility that some SIV proteases may cleave CARD8 in their simian hosts cannot be excluded.</p></disp-quote><p>We have added experiments to address this. Building upon our observation that chimpanzee CARD8 is not cleaved nor activated by HIV-1 or SIVcpz protease, we made a chimpanzee CARD8 L60F mutant, to determine if that single difference between human and chimpanzee CARD8 explains the difference in sensing of HIV-1 and SIVcpz protease. We find that the chimpanzee CARD8 L60F is both cleaved by HIV-1 and SIVcpz protease, and induces inflammasome activation upon HIV-1 infection (Figure 5 and Figure 5 â supplement 1). These data clarify not only that chimpanzee CARD8 is not cleaved or activated at another site, but also demonstrate that the humanspecific F60 on the chimpanzee CARD8 background is sufficient to confer sensing of HIV-1 and SIVcpz protease.</p><p>We agree that we cannot argue that no other primate CARD8 is activated by another lentiviral protease since we have not done a broad functional testing of others except for sequence analysis, and therefore we have modified our claims to those that we have tested. We do include data that Neanderthals also encode a CARD8 with the F59-F60 motif (Figure 1A), strengthening our argument that specificity for HIV-1<sup>PR</sup> evolved prior to the emergence of HIV in humans.</p><p>Additionally, in response to reviewer requests, we added a great deal of additional experiments to strengthen the mechanistic aspects of this manuscript, including:</p><p>â Multiple TLR agonists augment HIV-1 induced cell death and are required for HIV-1 induced IL-1 (Figure 3B and 3C).</p><p>â WT HIV-1 <italic>infection</italic> induces CASP1 activation in a CARD8-dependent manner (Figure 3D). In addition, we also now show that replication-competent HIV-1 (similar to VSVg pseudotyped virus) also induces CARD8 inflammasome activation in a manner dependent on cleavage of CARD8 (Figure 5D-F), as well as function of the HIV-1<sup>PR</sup> using the protease inhibitor Lopinavir (Figure 4B).</p><p>â Infection with a clinical HIV-1 strain that utilizes a distinct co-receptor (CCR5) relative to LAI, which also activates the CARD8 inflammasome (Figure 3E).</p><p>â The surprising finding that CARD8 activation occurs as early as 2h post-infection, suggesting that HIV-1<sup>PR</sup> released from the virion into target cells is sensed by CARD8 immediately following viral entry (Figure 4).</p><p>As such, we now emphasize the evolution-focused nature of our study that reveals the origins of HIV-1 sensing by human CARD8, which we believe also contributes important mechanistic insights about human CARD8 inflammasome activation by HIV-1 infection.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>The study is interesting and the data convincingly show that F60 renders human CARD8 sensitive to cleavage by SIVcpz and HIV-1 proteases and is associated with higher levels of cell death and IL1-Ã production in THP-1 cells infected with VSV-G pseudotyped HIV-1. The potential relevance for pathogenesis remains speculative since no evidence is presented that wild-type SIVcpz or HIV-1 induces inflammatory responses in primary viral target cells in a CARD8-dependent manner.</p><p>Specific points:</p><p>Lines 2-3. &quot;Simian immunodeficiency viruses (SIVs) are generally non-pathogenic in their natural hosts&quot;. This seems like an overstatement. It has been clearly shown that SIVcpz causes disease in wild chimpanzees (Keele et al., 2009). Also, experimental evidence for lack of disease in natural SIV infection comes mainly just from two of ~40 infected species and rare cases of the disease have even been reported in African green monkeys and sooty mangabeys.</p></disp-quote><p>We have moved the parts about possible links to pathogenesis from the Introduction to the Discussion where it is clearly marked as speculation. We have revised the text to be more precise about where the lack of disease has been observed, and now cite Keele et al., 2009 as suggested.</p><disp-quote content-type="editor-comment"><p>Figure 2B: the levels of EK505 Gag-Pol proteins are pretty low. Is this due to inefficient expression or antibody recognition?</p></disp-quote><p>The HIV-1 gag monoclonal antibody poorly recognizes the EK505 gag, and some of the other lentiviral gags we have now tested (e.g., SIVmac239; Figure 2 â Supplement 1). There is, however, enough cross-reactivity to be able to show that the gag polyprotein is cleaved. We now note this in the figure legends.</p><disp-quote content-type="editor-comment"><p>Figure 3: the levels of cell death and IL-1Ã secretion are substantially higher for VSV-G-pseudotyped HIV-1 LAI. Do the authors feel that this is just due to higher infection rates or that e.g. different sites of fusion may also contribute to the sensing effect? Do they have an explanation for why the effects of LAI on IL-Ã are not dose-dependent (panel B) and why Gag processing seems more effective for wild-type compared to VSV-G-mediated infection in panel C.</p></disp-quote><p>This is due to higher infection levels with the pseudotyped virus. We have now repeated these experiments with equivalent infectious doses of virus and find that the levels of IL-1Î² and cell death are the same whether or not viral entry occurs via WT envelope or VSV-G (e.g., Figure 3C and Figure 5E and 5F).</p><p>We have not experimentally addressed the lack of dose-dependency of IL-1Î². We speculate that even at lower infectivity levels that cells release a large bolus of IL-1Î² that may confound detection of dose-responsiveness. It has also been shown that inflammasome activation and IL-1Î² processing and release can occur in the absence of cell death (e.g,. Evavold et al., 2018, Immunity), which may also contribute to the lack of observed dose-dependency. We agree that this is an interesting observation, but is not an aspect that we have further investigated in the present manuscript. We have opted to replace this data with what we feel is a more informative panel showing that multiple TLR agonists are capable of enhancing HIV-1 induced cell death and are required for HIV-1 induced IL-1 cytokine release (Figure 3C).</p><disp-quote content-type="editor-comment"><p>In Figures 4E and F, only VSV-G data are shown. Would increase significance if effects can be verified with wild-type HIV-1.</p></disp-quote><p>We have now repeated this with WT infectious HIV-1 LAI and observe a similar result to the VSV-g pseudotyped HIV-1 LAI (Figure 5E-5F).</p><disp-quote content-type="editor-comment"><p>Pg 12, line 27: &quot;relative to HIV-infected patients who quickly progress to AIDS without treatment&quot;. Suggest to caution, an average of about 6-8 years doesn't really seem &quot;quick&quot; and is much slower than e.g. progression to simian AIDS in macaques.</p></disp-quote><p>We have removed this text.</p><disp-quote content-type="editor-comment"><p>Conclusions about the importance of CARD8-dependent inflammasome activation for the pathogenesis should be cautioned throughout or (better) substantiated by further experimental data.</p></disp-quote><p>We have moved the pathogenesis section to the Discussion.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>The authors show a protein alignment in Figure 1A. They need to specify where these data came from or what the species-specific variation is at those positions. The authors claim that only humans have phenylalanine at the 60th position. A more full phylogenetic analysis is needed to support this claim. Additionally, the aggregation of all old-world monkey species needs to be expanded upon in regard to which species are included in this analysis.</p></disp-quote><p>We have now added in all sequences from publicly available genomes from Old world monkey nonhuman primates that unambiguously encode an intact CARD8 gene. We have also included Neanderthal CARD8. Accession numbers for these sequences have been added to Supplement Table S3.</p><p>We of course agree that other primates for which we do not have a CARD8 sequence could have a phenylalanine at the analogous position to the human F60, and have altered the text to reflect this.</p><disp-quote content-type="editor-comment"><p>In Figure 1B, the 88/89 position was not mentioned as a protease cleavage site in previous studies. Do the authors have any experimental evidence? Otherwise, this should be removed.</p></disp-quote><p>This was our error and the figure has now been modified to remove mention of position 88/89 as a known cleavage site.</p><disp-quote content-type="editor-comment"><p>Figure 1C: The band present at the 40-45kDa position is explained by the authors as being due to proteasomal degradation but should be validated through the use of proteasome inhibitors or through identifying the exact cleavage site that produces this band.</p></disp-quote><p>The cleavage that gives rise to the ~40-45 kDa band was shown by the Bachovchin lab (Hsiao et al. 2022, JBC) to be dependent on the 20S proteasome. The authors also demonstrated that the 40-45 kDa CARD8 product is non-functional. We now explicitly mention this in the text (line 103-104 and figure legends).</p><disp-quote content-type="editor-comment"><p>Figure 1D: There are two bands present at the predicted HIV-PR site which the lower one is present in F60S. Is this band an HIV protease cleavage site as it is present in the HIV-transfected conditions? Does this cleavage lead to functional activation of the CARD8 inflammasome? There is clear evidence of cleavage in the F60L mutant condition, while the authors state that this makes cleavage less efficient. The text should reflect that F60 is not the only amino acid that can be cleaved and should downplay the human specificity due to this cleavage still being present, albeit less efficient. There is also an increased 40-45 kda band size in the mutant conditions, does this increase correspond to alternate cleavage site use, and does the alternative cleavage lead to CARD8 activation?</p></disp-quote><p>The issue of other minor cleavages is addressed with our functional assays in Figure 5 where we complement the <italic>CARD8</italic> KO THP-1 cells with different CARD8 variants. We observe inflammasome activation after HIV-1 infection upon complementation with WT human CARD8 and chimpanzee CARD8 L60F in which amino acid 60 has been changed to the human phenylalanine amino acid (Figure 5D-5F). Thus, whereas over-expression of gagpol may be capable of spurious CARD8 cleavage, this does not occur during HIV-1 infection. We also point out that not all cleavage events in the CARD8 N-terminus, or the analogous NLRP1 N-terminus, are activating (e.g., Sandstrom et al., 2019, Science, Hsiao et al. 2022, JBC, Wang et al., 2021, Science).</p><disp-quote content-type="editor-comment"><p>Figure 2A: There is an additional band at 50kDA present in this blot that was not present in previous blots, the authors should repeat these experiments. There are also faint bands at the SIV/HIV pr cleavage site annotated. The results can be improved by doing biochemical in vitro cleavage experiments using purified CARD8 and viral particles or PR to remove any background that may affect their results.</p></disp-quote><p>As stated above, the issue of other minor cleavages is addressed with our functional assays in Figure 5 where we complement <italic>CARD8</italic> KO THP-1 cells with different CARD8 variants. As such, we do not believe that using purified CARD8 in biochemical assays would substantially improve our interpretations, and instead favor conclusions based on the cumulative evidence across cleavage and functional assays, which are consistent with specific HIV-1 protease cleavage at the F59-F60 motif.</p><disp-quote content-type="editor-comment"><p>Figure 3A: These experiments were conducted 24 hours post-infection which can allow for the production of viral proteins. The authors should use earlier time points (&lt;12hrs) or block viral RT or integration to show cell death exclusively caused by the incoming viral proteins as stated in the results. Notably, cell death was observed also in CARD8-KO cells in Figure 4C.</p></disp-quote><p>We thank the reviewer for this insightful suggestion. We have now completed a series of experiments to address the timing of HIV-1 activation of the CARD8 inflammasome. Remarkably, we find that HIV-1 leads to CARD8 inflammasome activation within 2h of infection (Figure 4A), suggesting that the protease packaged within the incoming virus, in addition to de novo translated protease, is sensed by CARD8 upon HIV-1 entry. Consistent with this possibility, a preprint by Wang et al. shows that infection with a RT or integrase mutant virus, or treated cells with a reverse transcriptase inhibitor to block replication prior to the translation of HIV-1 proteins, still leads to CARD8 inflammasome activation (Wang et al. 2023, BioRxiv). We also confirm that CARD8 inflammasome activation is dependent on sensing HIV-1<sup>PR</sup> activity, as the HIV-1<sup>PR</sup> inhibitor treatment blocked HIV-1-induced inflammasome activation (Figure 4B).</p><p>As Vpr/Vpx are currently the only viral proteins that are thought to be packaged into the HIV virion that remain active to modulate host cell functions in the target cell, we also considered that Vpr may somehow be involved in CARD8 inflammasome activation by HIV-1. We found that HIV-1 mutant strain that lacks Vpr still results in IL-1Î² secretion from THP-1 WT but not <italic>CARD8</italic> KO cells (Figure 4B).</p><p>Taken together, these experiments clearly show that the packaged, incoming protease activates the CARD8 inflammasome. Work recently posted to BioRxiv by Liang Shanâs lab are in agreement with these findings (Wang and Shan, 2023, BioRxiv). These results have been added to the manuscript as a new Figure 4.</p><p>As noted above, we also now include a FLICA assay (which monitors CASP1 activation) and matched cytokine and cell death readouts to the panel in Figure 3D. Our results clearly show that CASP1 is activated only in the presence of CARD8 after HIV-1 infection.</p><disp-quote content-type="editor-comment"><p>In figure 3B, the authors mention that priming is required for IL-1B release but not cell death. Is it just for THP-1 cells, also correct in primary macrophages?</p></disp-quote><p>We have not done this experiment in primary macrophages. We would prefer to more fully explore the roles of different primary cell subsets in a subsequent study while this study focuses on the evolutionary and mechanistic consequences of CARD8 variation. We do cite other manuscripts (Clark et al. 2022, Nature Chem Biol; Balibar et al. 2023, Science Trans Med; Wang and Shan, 2023, BioRxiv) that look at CARD8-dependent cleavage by HIV-1 protease in primary T cells.</p><disp-quote content-type="editor-comment"><p>Can the authors perform similar experiments in Figure 3 using primary CD4 T cells?</p><p>In Figures4e and f, the authors also should test whether SIVcpz activates the CARD8cpz, which may have other potential cleavage sites. They should also create other non-human primate species CARD8 proteins to show that this is a human-specific activation as their results can only draw conclusions about human variation at the cleavage site and chimpanzee CARD8 activation.</p></disp-quote><p>We now have addressed this issue with the cleavage assays. We found that SIVcpz does not cleave chimpanzee CARD8, whereas a chimpanzee CARD8 L60F variant that contains the HIV-1 cleavage motif found in human CARD8, is. This data is now in Figure 5 â Supplement 1.</p><p>In addition, we show that SIVmac239 protease can cleave human CARD8 in a manner that depends on the amino acid identity at position 60 (Figure 2 â Supplement 1). We have not generated additional non-human primate CARD8 proteins as we prefer to focus on the evolutionary transition that occurred in the great ape lineage since the common ancestor of chimpanzees and humans that led to the human mutation in CARD8. We agree that characterization of simian lentivirus interactions across non-human primate CARD8s is a compelling next step. However, we feel to do this properly in a way that sufficiently samples diversity on both the virus and host side is a significant amount of work that should be its own story.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>1) The conclusion of &quot;â¦the CARD8 inflammasome as a potential driver of HIV pathogenesis&quot; is partially supported. As described in the summary above, HIV/SIVcpz PR-mediated CARD8 proteolysis at the N-terminus is inefficient to start with (Figures 1 and 2). In primed THP-1 cells, inflammasome activation associated with HIV-1 infection was detectable but much less profound compared to the VbP control.</p></disp-quote><p>In our view, it is not unexpected that VbP would induce an elevated response relative to our viral infection using a MOI&lt;1. We note that the apparent discrepancy between VbP- and HIV-induced CARD8 inflammasome activation is diminished in our new Figure 3D, where infectivity is routinely 30-50% relative to the experiment from the prior figure panel in which infectivity was 4%, 8%, and 45%. Based on our new data on CARD8 sensing of packaged HIV-1<sup>PR</sup> (Figure 4) we suggest that MOI may be an important determinant of the magnitude of the CARD8 response to HIV-1 infection, which we plan to explore in future studies.</p><disp-quote content-type="editor-comment"><p>2) Cell death measured by propidium iodide staining could be caused by multifold factors and thus is a rather generic pathological marker. HIV infection also has a pathological impact independent of PR activity, which is difficult to distinguish with the reported experimental approaches. Accordingly, these factors should be taken into consideration for the interpretation of cell death data.</p></disp-quote><p>As noted above, we have now more specifically measured CASP1 activation using a FLICA assay (which specifically reports on CASP1 activation) in WT, <italic>CARD8</italic> KO and <italic>CASP1</italic> KO THP-1 cells (Figure 3D). In experiments with both VSV-g pseudotyped and infectious virus, we observed increased FLICA signal in WT but not <italic>CASP1</italic> KO THP-1 cells. Moreover, the FLICA signal in <italic>CARD8</italic> KO THP-1 cells was indistinguishable from the <italic>CASP1</italic> KO THP-1 cells. Thus, our results are consistent with HIV-1 infection inducing CASP1-dependent pyroptosis downstream of CARD8.</p></body></sub-article></article>